var title_f37_21_38224="Atypical hydropneumothorax CT";
var content_f37_21_38224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of an atypical hydropneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atypical right hydropneumothorax in patient with previous sclerotherapy. CT scan shows dorsal gas-liquid level with the right lung adherent to the anterior chest wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38224=[""].join("\n");
var outline_f37_21_38224=null;
var title_f37_21_38225="Angioedema tongue";
var content_f37_21_38225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unilateral angioedema of the tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38225=[""].join("\n");
var outline_f37_21_38225=null;
var title_f37_21_38226="Airway morphology in asthma";
var content_f37_21_38226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Airway morphology of asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Airway wall inflammation, smooth muscle hyperplasia and increased contractility, epithelial damage, and alterations in the mucus-secreting apparatus and the basement membrane are prominent features of airway pathology in asthma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Wenzel S. The role of inflammation in asthma. National Asthma Education and Prevention Program Monograph, 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38226=[""].join("\n");
var outline_f37_21_38226=null;
var title_f37_21_38227="Vitamin B5 (pantothenic acid): Patient drug information";
var content_f37_21_38227=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vitamin B5 (pantothenic acid): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/13/18642?source=see_link\">",
"     see \"Vitamin B5 (pantothenic acid): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3034075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Panto-250 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help growth and good health.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This vitamin is used to stop or treat pantothenic acid deficiency.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pantothenic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11821 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-485ACEB782-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38227=[""].join("\n");
var outline_f37_21_38227=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034075\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012910\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012909\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012914\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012915\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012917\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012912\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012913\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012918\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012919\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/13/18642?source=related_link\">",
"      Vitamin B5 (pantothenic acid): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38228="Endovascular repair of thoracic aortic aneurysm";
var content_f37_21_38228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Endovascular repair of thoracic aortic aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 697px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thoracic endovascular grafts require proximal and distal seal zones of least two centimeters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38228=[""].join("\n");
var outline_f37_21_38228=null;
var title_f37_21_38229="Clindamycin (topical): Pediatric drug information";
var content_f37_21_38229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Clindamycin (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=see_link\">",
"    see \"Clindamycin (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=see_link\">",
"    see \"Clindamycin (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8008024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cleocin T&reg;;",
"     </li>",
"     <li>",
"      Cleocin&reg;;",
"     </li>",
"     <li>",
"      Cleocin&reg; Vaginal Ovule;",
"     </li>",
"     <li>",
"      Clindagel&reg;;",
"     </li>",
"     <li>",
"      ClindaMax&reg;;",
"     </li>",
"     <li>",
"      Clindesse&reg;;",
"     </li>",
"     <li>",
"      Evoclin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8008025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Clinda-T;",
"     </li>",
"     <li>",
"      Clindasol&trade;;",
"     </li>",
"     <li>",
"      Clindets;",
"     </li>",
"     <li>",
"      Dalacin&reg; T;",
"     </li>",
"     <li>",
"      Dalacin&reg; Vaginal;",
"     </li>",
"     <li>",
"      Taro-Clindamycin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10533130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Acne Products",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Anaerobic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10533141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=see_link\">",
"      see \"Clindamycin (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Children &ge;12 years, Adolescents, and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foam: Apply once daily in an amount that will cover the affected area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gel, pledget, lotion, solution: Apply a thin film twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clindagel&reg;: Apply a thin film once daily to the acne lesions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bacterial vaginosis:",
"     </b>",
"     Intravaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cream, 2%: One full applicator inserted intravaginally at bedtime for 7 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suppository: Insert one ovule (100 mg) intravaginally at bedtime for 3 days (",
"     <i>",
"      Red Book",
"     </i>",
"     , 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cleocin&reg; Cream: One full applicator (100 mg) inserted intravaginally once daily before bedtime for 3 or 7 consecutive days in nonpregnant patients and 7 consecutive days in pregnant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Clindesse&reg; Cream: One full applicator inserted intravaginally as a single dose at anytime during the day in nonpregnant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Suppository: Insert one ovule (100 mg) intravaginally once daily before bedtime for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing  adjustment in renal impairment:",
"     </b>",
"     No adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Systemic use: No adjustment required. Use caution with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8008157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical, as phosphate [strength expressed as base]: 1% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evoclin&reg;: 1% (50 g [DSC], 100 g) [contains ethanol 58%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, vaginal, as phosphate [strength expressed as base]: 2% (40 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin&reg;: 2% (40 g) [contains benzyl alcohol, mineral oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clindesse&reg;: 2% (5 g) [contains mineral oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical, as phosphate [strength expressed as base]: 1% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin T&reg;: 1% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clindagel&reg;: 1% (40 mL, 75 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ClindaMax&reg;: 1% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical, as phosphate [strength expressed as base]: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin T&reg;: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ClindaMax&reg;: 1% (60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pledget, topical, as phosphate [strength expressed as base]: 1% (60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin T&reg;: 1% (60s) [contains isopropyl alcohol 50%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical, as phosphate [strength expressed as base]: 1% (30 mL, 60 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin T&reg;: 1% (30 mL, 60 mL) [contains isopropyl alcohol 50%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, vaginal, as phosphate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cleocin&reg; Vaginal Ovule: 100 mg (3s) [contains oleaginous base]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8008027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes vaginal suppositories",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10533142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravaginal: Do not use for topical therapy, instillation in the eye, or oral administration. Wash hands; insert applicator into vagina and expel suppository or cream. Remain lying down for 30 minutes following administration. Wash applicator with soap and water following suppository use; if administering the cream, use each disposable applicator only once.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical foam: Before applying foam, wash affected area with mild soap, then dry. Do not dispense foam directly onto hands or face. Remove cap, hold can at an upright angle, and dispense foam directly into the cap or onto a cool surface. If can is warm or foam is runny, run can under cold water. Use fingertips to pick up small amounts of foam and gently massage into affected area until foam disappears. Avoid fire, flame, or smoking during or immediately following application. Avoid contact with eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical gel, pledget, solution: Do not use intravaginally, instill in the eye, or administer orally. Solution/pledget contains an alcohol base and if inadvertent contact with mucous membranes occurs, rinse with liberal amounts of water. Remove pledget from foil immediately before use; discard after single use. May use more than one pledget for each application to cover area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical lotion: Shake well before use; apply topically. Do not use intravaginally, instill in the eye, or administer orally.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10533137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Foam: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Avoid fire, flame, or smoking during or following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: Store at room temperature. Clindagel&reg;: Do not store in direct sunlight; do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ovule: Store at room temperature of 25&deg;C (77&deg;F). Avoid heat &gt;30&deg;C (86&deg;F) and high humidity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical solution or pledgets: Store at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10533131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acne vulgaris (FDA approved in ages &ge;12 years and adults); used intravaginally for treatment of bacterial vaginosis (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8007985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cleocin&reg; may be confused with bleomycin, Clinoril&reg;, Cubicin&reg;, Lincocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Clindamycin may be confused with clarithromycin, Claritin&reg;, vancomycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8008058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Topical:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Dryness, burning, itching, scaliness, or peeling of skin (lotion, solution); erythema (foam, lotion, solution); oiliness (gel, lotion)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, application site/skin pain, diarrhea (hemorrhagic or severe), dizziness, folliculitis, hypersensitivity reactions, nausea, pseudomembranous colitis, rash, seborrhea, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Trichomonal vaginitis, urinary tract infection, vaginal moniliasis, vaginal pain, vulvovaginal disorder, vulvovaginal pruritus, vulvovaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Fungal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reaction, atrophic vaginitis, bacterial infection, endometriosis, epistaxis, erythema, hematochezia, hypersensitivity, hyperthyroidism, local edema, metrorrhagia, pyelonephritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10533132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to clindamycin, lincomycin, or any component; history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10533135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in atopic patients. Use of vaginal cream may result in overgrowth of nonsusceptible organisms within the vaginal area.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10533133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use can cause severe and possibly fatal colitis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     characterized by severe persistent diarrhea, severe abdominal cramps, and possibly, the passage of blood and mucus; onset of symptoms may occur during or several weeks after completion of therapy; discontinue drug if significant diarrhea occurs. Antiperistaltic agents, such as opiates or diphenoxylate with atropine, may prolong and worsen the condition. Foam may cause skin irritation; avoid contact with eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8018207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8018205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9749572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were not observed in animal reproduction studies. Clindamycin has been shown to cross the placenta throughout pregnancy and at term following oral and parenteral dosing; use during pregnancy has not been shown to cause adverse fetal effects. Refer to the Clindamycin (Systemic) monograph for details. The amount of clindamycin available systemically is less following topical and vaginal application than with I.V. or oral administration. Oral clindamycin is recommended in certain pregnant patients for the treatment of bacterial vaginosis; however, vaginal therapy is not recommended for use in the second half of pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10533143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for changes in bowel frequency.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10533138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly binds to 50S ribosomal subunits preventing peptide bond formation, thus inhibiting bacterial protein synthesis; bacteriostatic or bactericidal depending on drug concentration, infection site, and organism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10533140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Absorption: Topical solution, phosphate: Minimal; Vaginal cream, phosphate: ~5%; Vaginal suppository, phosphate: ~30%",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10533164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=see_link\">",
"      see \"Clindamycin (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravaginal: Wash hands before using. At bedtime: If using applicator, gently insert full applicator into vagina and expel cream. Wash applicator with soap and water following use. If using suppository, insert high into vagina. Remain lying down for 30 minutes following administration. Avoid intercourse during therapy; clindamycin vaginal cream (oil-based) may weaken latex condoms for up to 72 hours after completing therapy. Report adverse reactions (dizziness, nausea, vomiting, stomach cramps, or headache) or lack of improvement or worsening of condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical, foam: Wash hands thoroughly or wear gloves. Do not dispense directly onto hands or face (foam will begin to melt on contact with warm skin). Dispense an amount that will cover the affected area directly into the cap or onto a cool surface. If can seems warm or foam seems runny, run can under cold water. Pick up small amounts of foam with fingertips and gently massage into affected areas until foam disappears. Wash hands thoroughly. Wait 30 minutes before shaving or applying make-up.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical gel, lotion, or solution: Wash hands thoroughly before applying or wear gloves. Apply thin film of gel, lotion, or solution to affected area. May apply porous dressing. Wash hands thoroughly. Wait 30 minutes before shaving or applying make-up. Report persistent burning, swelling, itching, excessive dryness, or worsening of condition.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Diagnosis and Treatment of Malaria.\" Available at:",
"      <a href=\"file://www.cdc.gov/malaria/diagnosis_treatment/index.html\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/diagnosis_treatment/index.html",
"      </a>",
"      . Date accessed: Nov 11, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38229/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber MA, Baltimore RS, Eaton CB, et al, \"Prevention of Rheumatic Fever and Diagnosis and Treatment of Acute",
"      <i>",
"       Streptococcal pharyngitis",
"      </i>",
"      : A Scientific Statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: Endorsed by the American Academy of Pediatrics,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(11):1541-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38229/abstract-text/19246689/pubmed\" id=\"19246689\" target=\"_blank\">",
"        19246689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu C, Bayer A, Cosgrove SE, et al, \"Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections in Adults and Children: Executive Summary,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(3):285-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38229/abstract-text/21217178/pubmed\" id=\"21217178\" target=\"_blank\">",
"        21217178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , \"Drugs for Parasitic Infections,\" 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009, 783-816. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/4.10",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2012 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 29th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilson W, Taubert KA, Gewitz M, et al, \"Prevention of Infective Endocarditis. Guidelines From the American Heart Association,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115:1-20.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Workowski KA, Berman S, and Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38229/abstract-text/ 21160459 /pubmed\" id=\" 21160459 \" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15954 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38229=[""].join("\n");
var outline_f37_21_38229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008024\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533130\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533141\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008157\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008027\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533142\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533137\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533131\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8007985\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8008058\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533132\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533135\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533133\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299058\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018207\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018205\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749572\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533143\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533138\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533140\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10533164\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15954|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/46/41704?source=related_link\">",
"      Clindamycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/49/35604?source=related_link\">",
"      Clindamycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/1/8215?source=related_link\">",
"      Clindamycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/46/5862?source=related_link\">",
"      Clindamycin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/21/2389?source=related_link\">",
"      Clindamycin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38230="Epidemiology of central nervous system tumors in children";
var content_f37_21_38230=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of central nervous system tumors in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     Ching Lau, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     Wan-Yee Teo, MBBS, MRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38230/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/21/38230/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) tumors include both non-malignant and malignant tumors of the brain and spinal cord. Primary malignant CNS tumors are the second most common childhood malignancies, after hematological malignancies, and are the most common pediatric solid organ tumor (",
"    <a class=\"graphic graphic_table graphicRef69839 \" href=\"mobipreview.htm?31/51/32572\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/1\">",
"     1",
"    </a>",
"    ]. Although progress has been made in the treatment of childhood tumors, significant mortality and morbidity are still associated with malignant brain tumors.",
"   </p>",
"   <p>",
"    The epidemiology of CNS tumors in children will be reviewed here. The clinical manifestations, diagnosis, and overview of the management of CNS tumors and outcome in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/56/13192?source=see_link\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13736?source=see_link\">",
"     \"Overview of the management of central nervous system tumors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States (US), based upon data from the Central Brain Tumor Registry of the US (CBTRUS), the estimated incidence of primary non-malignant and malignant CNS tumors is 4.5 cases per 100,000 person-years for children and adolescents at or below 19 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/2\">",
"     2",
"    </a>",
"    ]. This translates to about 3750 of newly diagnosed cases per year. The estimated five-year survival rate for all primary CNS tumors is about 66 percent in patients at or below 19 years of age, resulting in about 26,000 children living in the United States with a CNS tumor.",
"   </p>",
"   <p>",
"    In the US, data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute from 1992 to 2004 showed CNS tumors account for about 20 percent of all childhood malignancies in children below 14 years of age (",
"    <a class=\"graphic graphic_table graphicRef69839 \" href=\"mobipreview.htm?31/51/32572\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Germany, the incidence of childhood CNS tumors is lower with a reported rate of 2.6 per 100,000 children less than 15 years of age based on epidemiologic data from 1990 to 1999 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of childhood CNS tumors varies with age. From the SEER database, the following annual age-adjusted rates of malignant CNS tumors per million from 2004 to 2006 based on age were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Less than 1 year of age: 40",
"     </li>",
"     <li>",
"      Between 1 and 4 years of age: 47",
"     </li>",
"     <li>",
"      Between 5 and 9 years of age: 39",
"     </li>",
"     <li>",
"      Between 10 and 14 years of age: 36",
"     </li>",
"     <li>",
"      Between 15 and 19 years of age: 42",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate is higher in males compared with females, with a reported incidence of 4.7 versus 4.3 per 100,000 person-year, respectively, in the US [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/1,2,5\">",
"     1,2,5",
"    </a>",
"    ]. In China, the male to female ratio was 1.6 to 1 for children (defined as 17 years of age or younger) with primary CNS tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of childhood CNS tumors is greatest in white individuals. The following incidence rates per million for CNS tumors in patients less than 20 years in different ethnic groups were based upon data from the SEER program from 2002 to 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      White: 29.4",
"     </li>",
"     <li>",
"      Hispanic: 24.3",
"     </li>",
"     <li>",
"      Black: 19.8",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Asian/Pacific",
"      </span>",
"      Islander: 18.7",
"     </li>",
"     <li>",
"      Native American: 18.4",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Trends over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidence rate increased for all age groups from 1975 to 1980 and 1987 to 1992. This change in incidence did not occur progressively from 1975 to 1994, but jumped to a higher rate after 1985. This increase has been attributed to the increased availability of magnetic resonance imaging, which likely resulted in improved diagnostic sensitivity rather than an actual increase in incidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two main classification systems are used to categorize childhood CNS tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      World Health Organization classification is based on tumor histology.",
"     </li>",
"     <li>",
"      International Classification of Childhood Cancer (ICCC) is based on the primary tumor site and morphology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     WHO classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classification for CNS tumors developed in 1979 and revised in 1999 and 2007 has been universally adopted in grouping CNS tumors (",
"    <a class=\"graphic graphic_table graphicRef73168 \" href=\"mobipreview.htm?14/49/15134\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/8\">",
"     8",
"    </a>",
"    ]. The classification of brain tumors is based on histologic findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=see_link\">",
"     \"Classification of gliomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histological types of malignant CNS tumors vary with age in children and differ from those that present in adults (",
"    <a class=\"graphic graphic_figure graphicRef70767 \" href=\"mobipreview.htm?21/29/21970\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61480 \" href=\"mobipreview.htm?25/37/26206\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/2\">",
"     2",
"    </a>",
"    ]. In children, primary CNS tumors predominate, and about half are located in the posterior fossa (",
"    <a class=\"graphic graphic_figure graphicRef81514 \" href=\"mobipreview.htm?36/58/37807\">",
"     figure 3",
"    </a>",
"    ). In contrast, most CNS tumors in adults are metastatic lesions to the cerebral cortex. These differences translate to differences in clinical presentation between pediatric and adult malignant CNS tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/56/13192?source=see_link\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon data from 5873 cases of CNS tumors from the Central Brain Tumor Registry of the United States (CBTRUS) from 2000 to 2004, the following were the major malignant and nonmalignant histologic groups of childhood CNS tumors using the WHO histologic classification schema (",
"    <a class=\"graphic graphic_table graphicRef73168 \" href=\"mobipreview.htm?14/49/15134\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/2\">",
"     2",
"    </a>",
"    ]. Incidences for these tumor groups are also included and are based upon children and adolescents at or below 19 years of age per 100,000 person-years.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumors of neuroepithelial tissue (incidence: 3.4 per 100,000 person-years) are also referred to as gliomas, which are tumors derived from glial cells (ie, astrocytes, oligodendrocytes, and ependymal cells). These tumors account for almost 75 percent of all primary childhood CNS tumors, and include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Astrocytic tumors, (incidence of 1.8 per 100,000 person-years) can occur throughout the CNS and range from low-grade indolent lesions to highly malignant aggressive tumors.",
"      <br/>",
"      <br/>",
"      Low-grade astrocytomas are the largest group of CNS tumors in children. Pilocytic astrocytoma, formerly referred to as juvenile pilocytic astrocytoma, is the most common brain tumor, with an incidence of 0.87 per 100,000 person-years (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef78521 \" href=\"mobipreview.htm?30/20/31041\">",
"       image 1",
"      </a>",
"      ). Other low-grade astrocytomas include diffuse astrocytomas, oligodendroglial tumors, and gangliogliomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=see_link\">",
"       \"Diagnosis and classification of low-grade gliomas\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      High-grade malignant astrocytomas (incidence of 0.7 per 100,000 person-years) are divided into anaplastic gliomas (ie, anaplastic astrocytoma, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma), diffuse intrinsic pontine glioma (picture 2) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75202 \" href=\"mobipreview.htm?6/13/6354\">",
"       image 2",
"      </a>",
"      ) and glioblastoma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65346 \" href=\"mobipreview.htm?35/48/36610\">",
"       image 3",
"      </a>",
"      ). These highly malignant and aggressive tumors carry an extremely poor prognosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=see_link\">",
"       \"Clinical manifestations and initial surgical approach to patients with malignant gliomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ependymoma/anaplastic",
"      </span>",
"      ependymoma (incidence of 0.23 per 100,000 person-years) are derived from primitive glia. Ependymomas account for 10 percent of intracranial tumors, and 40 to 60 percent of spinal cord tumors in children and young adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/9\">",
"       9",
"      </a>",
"      ]. In children, approximately 90 percent of ependymomas are intracranial (60 percent in the posterior fossa); the remaining tumors arise within the spinal cord. In children under 3 years of age, ependymomas are typically posterior fossa tumors located about or within the fourth ventricle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef53610 \" href=\"mobipreview.htm?30/35/31284\">",
"       image 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/51/15161?source=see_link\">",
"       \"Ependymoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Embryonal CNS tumors (incidence of 0.6 per 100,000 person-years) include medulloblastoma (the predominant tumor of this group), CNS primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumors. Although these tumors have been classified as primitive neuroectodermal tumors based upon the theory that they share a common progenitor cell, there is cytogenetic and molecular evidence that suggests medulloblastoma is a separate and distinct histologic entity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=see_link\">",
"       \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=see_link&amp;anchor=H19#H19\">",
"       \"Uncommon brain tumors\", section on 'Embryonal carcinomas'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=see_link\">",
"       \"Classification of gliomas\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Medulloblastoma is the most common malignant brain tumor of childhood, accounting for approximately 20 percent of all primary tumors of the central nervous system among patients less than 19 years of age (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef55787 \" href=\"mobipreview.htm?32/41/33427\">",
"       image 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=see_link\">",
"       \"Histopathology and molecular pathogenesis of medulloblastoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuronal and mixed neuronal-glial tumors (incidence of 0.33 per 100,000 person-years) are characterized by a variable degree of neuronal differentiation. They include gangliomas and gangliocytomas, dysplastic gangliogliocytoma of the cerebellum (Lhermitte Duclos disease), cerebellar liponeurocytomas, central neurocytomas, and glomus tumors (paragangliomas). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=see_link&amp;anchor=H2#H2\">",
"       \"Uncommon brain tumors\", section on 'Neuronal and neuronoglial tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumors of the sellar region (incidence of 0.34 per 100,000 person-years) include pituitary tumors and craniopharyngiomas. Craniopharyngiomas are solid or mixed solid-cystic benign tumors that are the third most common intracranial tumor in children after gliomas and medulloblastomas. They account for 5 to 10 percent of all childhood brain tumors. These tumors are generally located in the suprasellar area and arise from remnants of Rathke's pouch. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=see_link\">",
"       \"Causes, presentation, and evaluation of sellar masses\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24520?source=see_link\">",
"       \"Craniopharyngioma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tumors of cranial and paraspinal nerves (incidence of 0.19 per 100,000 person-years) include schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28694?source=see_link\">",
"       \"Intradural nerve sheath tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Germ cell tumors and cysts (incidence of 0.18 per 100,000 person-years) include germinoma, embryonal carcinoma, yolk sac tumor (endodermal sinus tumors), choriocarcinoma, and teratoma. Approximately two-thirds of these tumors occur in the pineal and suprasellar areas, and the remaining occur in the supratentorial region.",
"     </li>",
"     <li>",
"      Tumors of the meninges (incidence of 0.17 per 100,000 person-years), also referred to as meningiomas, arise from the arachnoidal cap cell in the arachnoid membrane and have varying degrees of malignancy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=see_link\">",
"       \"Meningioma: Clinical presentation and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphoma and hemopoietic neoplasms (incidence of 0.02 per 100,000 person-years). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unclassified tumors (incidence of 0.24 per 100,000 person-years)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a Chinese retrospective report of 1485 cases of primary CNS tumors in patients up to 17 years of age cared for at a single tertiary center between 2001 and 2005, the five most common brain tumors in 872 cases were astrocytic tumors (31 percent), craniopharyngiomas (18 percent), medulloblastoma (15 percent), germ cell tumors (8 percent), and ependymal tumors (6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/6\">",
"     6",
"    </a>",
"    ]. The most common spinal cord tumors were ependymal tumors (19 percent), schwannomas (17 percent), and astrocytoma (15 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     ICCC Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;International Classification of Childhood Cancer (ICCC) is based upon primary tumor site and is used by the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute in their epidemiologic survey of childhood cancer in the United States.",
"   </p>",
"   <p>",
"    In this classification schema, tumors are categorized by site of origin separating brain tumors from spine and cranial nerve tumors. Tumors are then further subdivided into histologic groups: ependymoma, astrocytoma, primitive neuroectodermal tumor, other gliomas, and miscellaneous.",
"   </p>",
"   <p>",
"    A limitation of the ICCC classification is that mortality rates for tumors based upon their underlying histology cannot be identified because the initial categorization is based on site. As an example, astrocytomas of the spinal cord would not be categorized with brain astrocytomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Distribution by site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the tumor may impact upon the clinical presentation. As an example, vision loss may occur with any tumor that is localized along the optic pathway. Infratentorial tumors may present with localizing signs of ataxia or cranial neuropathies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/56/13192?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of central nervous system tumors in children\", section on 'Tumor location'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon data from the CBTRUS data from 2000 to 2004, the distribution of almost 6000 CNS tumors by sites is as follows (",
"    <a class=\"graphic graphic_figure graphicRef81514 \" href=\"mobipreview.htm?36/58/37807\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supratentorial brain lesions (30 percent) &ndash; Temporal lobe, frontal lobe, cerebrum, ventricle, parietal lobe, occipital lobe",
"     </li>",
"     <li>",
"      Infratentorial brain lesions (29 percent) &ndash; Cerebellum and brainstem",
"     </li>",
"     <li>",
"      Other nonspecified brain sites( 17 percent)",
"     </li>",
"     <li>",
"      Pituitary and pineal glands (11 percent)",
"     </li>",
"     <li>",
"      Cranial nerves (5 percent)",
"     </li>",
"     <li>",
"      Spinal cord and cauda equina (6 percent)",
"     </li>",
"     <li>",
"      Meninges (2 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the previously mentioned Chinese report of 1485 primary CNS tumors, 92 percent were located in the brain, and 8 percent were located in the spinal cord. Sixty-two percent of the brain tumors were supratentorial.",
"   </p>",
"   <p>",
"    Because spinal cord tumors are relatively rare, it is difficult to ascertain the relative frequency of specific tumors. In one case series of 35 children with a spinal cord tumor, 11 patients had neurodevelopmental tumors (ie, dermoid and epidermoid tumors, and teratomas), followed by 10 with astrocytoma, and 5 with neuroblastoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/5\">",
"     5",
"    </a>",
"    ]. Other causes of spinal tumors included schwannoma, meningioma, giant cell tumors, extradural cystic masses, leukemic-related masses, and masses associated with neurofibromatosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the etiology of most childhood CNS tumors remains unknown, two established risk factors for the development of a CNS tumor include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to ionizing radiation &ndash; Cranial irradiation results in an increased risk of developing meningiomas, gliomas, and nerve sheath tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38230/abstract/10\">",
"       10",
"      </a>",
"      ]. In particular, high-dose cranial irradiation in patients with acute lymphoblastic leukemia is associated with a 6- and 10-fold increase in the risk of glioma and meningioma, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=see_link&amp;anchor=H8#H8\">",
"       \"Risk factors for brain tumors\", section on 'Radiation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of the outcome of acute lymphoblastic leukemia in children\", section on 'Brain tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genetic syndromes &ndash; Genetic syndromes that confer an increased risk of developing tumors of the nervous system include the following genetic conditions, which are discussed in greater detail separately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Neurofibromatosis (NF) is an autosomal dominant neurocutaneous disorder, which includes NF type 1 (also known as von Recklinghausen's disease) and NF type 2. Both are associated with CNS tumors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=see_link\">",
"       \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tuberous sclerosis is an autosomal dominant neurocutaneous disorder that is characterized by pleomorphic features involving many organ systems, including multiple benign neoplasms of the brain, kidney, and skin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=see_link&amp;anchor=H17#H17\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\", section on 'Brain lesions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      von Hippel-Lindau syndrome is an autosomal dominant disorder associated with hemangioblastomas, pancreatic cysts, neuroendocrine tumors, renal tumors, and pheochromocytomas. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=see_link\">",
"       \"Clinical features, diagnosis, and management of von Hippel-Lindau disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14678?source=see_link\">",
"       \"Molecular biology and pathogenesis of von Hippel-Lindau disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Basal cell nevus syndrome, also referred to as Gorlin syndrome or nevoid basal cell cancer syndrome, is caused by germline mutations of the patched (PTCH) gene, a tumor suppressor gene. It is associated with an increased risk of medulloblastoma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44121?source=see_link\">",
"       \"Nevoid basal cell carcinoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Li Fraumeni syndrome is an autosomal dominant disorder characterized by soft tissue and bone sarcomas, breast cancers, and other malignancies, including brain tumors, leukemia, and adrenocortical cancer. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=see_link\">",
"       \"Li-Fraumeni syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Turcot's syndrome is a disorder that includes brain tumors (primarily medulloblastomas and gliomas) and one of two forms of colonic polyposis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link&amp;anchor=H625428197#H625428197\">",
"       \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Turcot's syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) tumors include both non-malignant and malignant tumors of the brain and spinal cord.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, the estimated incidence of childhood primary non-malignant and malignant CNS tumors is 4.5 cases per 100,000 person-years. The estimated five-year survival rate for all primary CNS tumors is about 66 percent in patients at or below 19 years of age, resulting in about 26,000 children living in the United States with a CNS tumor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The distribution of childhood CNS tumors varies by histology. Tumors of neuroepithelial tissue account for almost 75 percent of all primary childhood CNS tumors. They include pilocytic astrocytoma, a low-grade astrocytoma that is the most common brain tumor, and medulloblastoma, the most common malignant CNS tumor of childhood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'WHO classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant CNS tumors are the second most common malignancy after hematologic disorders, accounting for about 20 percent of all childhood malignancies (",
"      <a class=\"graphic graphic_table graphicRef69839 \" href=\"mobipreview.htm?31/51/32572\">",
"       table 1",
"      </a>",
"      ). The risk of malignant CNS tumors varies with age with the greatest risk in preschool children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The location of the tumor impacts the clinical presentation. Brain tumors account for about 90 percent of all CNS tumors, and the remaining CNS tumors are found in the spinal cord and cranial nerves. About one-half to two-thirds of brain tumors are supratentorial. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Distribution by site'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the etiology of most childhood CNS tumors remains unknown, two established risk factors for the development of a CNS tumor in children include exposure to ionizing radiation and specific genetic syndromes, such as neurofibromatosis, Gorlin syndrome, von Hippel-Lindau syndrome, and tuberous sclerosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38230/abstract/1\">",
"      Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 2008; 112:416.",
"     </a>",
"    </li>",
"    <li>",
"     Central Brain Tumor Registry of the United States. 2007-2008 primary brain tumors in the United States statistical report, 2000-2004. www.cbtrus.org/reports/reports.html (Accessed August 14, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38230/abstract/3\">",
"      Kaatsch P, Rickert CH, K&uuml;hl J, et al. Population-based epidemiologic data on brain tumors in German children. Cancer 2001; 92:3155.",
"     </a>",
"    </li>",
"    <li>",
"     Homer MJ, Ries, LAG, Krapcho, M, et al (eds). SEER Cancer Statistic Review, 1975-2006. file://seer.cancer.gov/csr/1975_2006/. (Accessed May 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38230/abstract/5\">",
"      Wilson PE, Oleszek JL, Clayton GH. Pediatric spinal cord tumors and masses. J Spinal Cord Med 2007; 30 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38230/abstract/6\">",
"      Zhou D, Zhang Y, Liu H, et al. Epidemiology of nervous system tumors in children: a survey of 1,485 cases in Beijing Tiantan Hospital from 2001 to 2005. Pediatr Neurosurg 2008; 44:97.",
"     </a>",
"    </li>",
"    <li>",
"     Bleyer A, O&rsquo;Leary M, Barr R, Ries LAG (eds): Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival: 1975-2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD 2006.",
"    </li>",
"    <li>",
"     Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. Classification of Tumours of the Nervous System, IARC Press, Lyon, France 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38230/abstract/9\">",
"      Allen JC, Siffert J, Hukin J. Clinical manifestations of childhood ependymoma: a multitude of syndromes. Pediatr Neurosurg 1998; 28:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38230/abstract/10\">",
"      Taylor AJ, Little MP, Winter DL, et al. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010; 28:5287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6251 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38230=[""].join("\n");
var outline_f37_21_38230=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Trends over time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      WHO classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ICCC Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Distribution by site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6251|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/20/31041\" title=\"diagnostic image 1\">",
"      Pilocytic astrocytoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/13/6354\" title=\"diagnostic image 2\">",
"      MRI pontine glioma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/48/36610\" title=\"diagnostic image 3\">",
"      MRI glioblastoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/35/31284\" title=\"diagnostic image 4\">",
"      MRI ependymoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?32/41/33427\" title=\"diagnostic image 5\">",
"      Imaging medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6251|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/29/21970\" title=\"figure 1\">",
"      CNS tumor child histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/37/26206\" title=\"figure 2\">",
"      CNS tumor type child rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/58/37807\" title=\"figure 3\">",
"      CNS tumor child site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6251|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/51/32572\" title=\"table 1\">",
"      Common childhood cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/49/15134\" title=\"table 2\">",
"      WHO nervous system tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/18/29992?source=related_link\">",
"      Causes, presentation, and evaluation of sellar masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/17/36117?source=related_link\">",
"      Classification of gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/5/22618?source=related_link\">",
"      Clinical features, diagnosis, and management of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/56/13192?source=related_link\">",
"      Clinical manifestations and diagnosis of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35784?source=related_link\">",
"      Clinical manifestations and initial surgical approach to patients with malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/60/24520?source=related_link\">",
"      Craniopharyngioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/1/2071?source=related_link\">",
"      Diagnosis and classification of low-grade gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/51/15161?source=related_link\">",
"      Ependymoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41332?source=related_link\">",
"      Histopathology and molecular pathogenesis of medulloblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28694?source=related_link\">",
"      Intradural nerve sheath tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25540?source=related_link\">",
"      Meningioma: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/21/14678?source=related_link\">",
"      Molecular biology and pathogenesis of von Hippel-Lindau disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13736?source=related_link\">",
"      Overview of the management of central nervous system tumors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40649?source=related_link\">",
"      Overview of the outcome of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/42/8874?source=related_link\">",
"      Risk factors for brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35946?source=related_link\">",
"      Uncommon brain tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38231="Butalbital, acetaminophen, and caffeine: Drug information";
var content_f37_21_38231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Butalbital, acetaminophen, and caffeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/17/7445?source=see_link\">",
"    see \"Butalbital, acetaminophen, and caffeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13135458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alagesic LQ;",
"     </li>",
"     <li>",
"      Anolor 300;",
"     </li>",
"     <li>",
"      Dolgic&reg; Plus;",
"     </li>",
"     <li>",
"      Esgic-Plus&trade;;",
"     </li>",
"     <li>",
"      Esgic&reg;;",
"     </li>",
"     <li>",
"      Fioricet&reg;;",
"     </li>",
"     <li>",
"      Margesic;",
"     </li>",
"     <li>",
"      Orbivan&trade;;",
"     </li>",
"     <li>",
"      Repan&reg;;",
"     </li>",
"     <li>",
"      Zebutal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F143663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F143650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tension or muscle contraction headache: Oral: 1-2 tablets or capsules (or 15-30 mL solution) every 4 hours; not to exceed 6 tablets or capsules (or 180 mL solution) daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F143651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F143652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be reduced.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F143653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage should be reduced.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F143628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anolor 300, Esgic&reg;, Margesic: Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esgic-Plus&trade;, Zebutal&reg;: Butalbital 50 mg, acetaminophen 500 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orbivan&trade;: Butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alagesic LQ: Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg per 15 mL (480 mL) [contains ethanol 7%; propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg; butalbital 50 mg, acetaminophen 500 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dolgic&reg; Plus: Butalbital 50 mg, acetaminophen 750 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esgic&reg;, Fioricet&reg;, Repan&reg;: Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Esgic-Plus&trade;: Butalbital 50 mg, acetaminophen 500 mg, and caffeine 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F143613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F143631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of the symptomatic complex of tension or muscle contraction headache",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F143670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fioricet&reg; may be confused with Fiorinal&reg;, Florinef&reg;, Lorcet&reg;, Percocet&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Repan&reg; may be confused with Riopan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F143661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Specific percentages not reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Frequently observed:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Intoxicated feeling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Infrequently observed:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, depression, euphoria, excitement, faintness, fever, headache, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot spells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, dysphagia, heartburn, flatulence, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg pain, muscle fatigue, numbness, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Heavy eyelids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Earache, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Diuresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, high energy, shaky feeling, sluggishness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F143634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to butalbital, acetaminophen, caffeine, or any component of the formulation; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F143617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Caffeine: May cause CNS and cardiovascular stimulation, as well as GI irritation in high doses. Use with caution in patients with a history of peptic ulcer or GERD; avoid in patients with symptomatic cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit:  Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F143659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F143622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Barbiturates may decrease the serum concentration of Voriconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F143643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F143625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F143636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Withdrawal seizures were reported in an infant 2 days after birth following maternal use of a butalbital product during the last 2 months of pregnancy; butalbital was detected in the newborns serum. Also refer to individual monographs for information specific to acetaminophen or caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F143655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F143637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates, caffeine, and acetaminophen are excreted in breast milk. Also refer to individual agents for information specific to acetaminophen or caffeine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F143635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Butalbital-APAP-Caffeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $119.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Capacet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $29.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Esgic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $215.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Esgic-Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-500-40 mg (100): $183.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Orbivan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-300-40 mg (100): $240.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zebutal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-500-40 mg (100): $248.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Alagesic LQ Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg/15 mL (473 mL): $71.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Butalbital-APAP-Caffeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $64.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-500-40 mg (100): $119.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Esgic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $227.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Esgic-Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-500-40 mg (100): $184.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fioricet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-325-40 mg (100): $261.44",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F143616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Butalbital is a short- to intermediate-acting barbiturate. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, hypnosis, and dose-dependent respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caffeine increases levels of 3'5' cyclic AMP by inhibiting phosphodiesterase; CNS stimulant which increases medullary respiratory center sensitivity to carbon dioxide, stimulates central inspiratory drive, and improves skeletal muscle contraction (diaphragmatic contractility)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F143633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual monographs for Acetaminophen and Caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Butalbital: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Butalbital: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Butalbital: 35 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Butalbital: Urine (59% to 88% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/21/38231/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8822 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-EC60C7DA3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38231=[""].join("\n");
var outline_f37_21_38231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135458\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143648\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143663\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143650\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143651\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143652\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143653\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143628\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143613\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143631\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143670\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143661\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143634\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143617\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143659\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143622\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143643\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143625\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143636\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143655\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143637\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143635\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143633\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8822|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/17/7445?source=related_link\">",
"      Butalbital, acetaminophen, and caffeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38232="Clinical features and diagnosis of malabsorption";
var content_f37_21_38232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of malabsorption",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Joel B Mason, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Vladan Milovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Timothy O Lipman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38232/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/21/38232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malabsorption refers to impaired absorption of nutrients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/1\">",
"     1",
"    </a>",
"    ]. It can result from congenital defects in the membrane transport systems of the small intestinal epithelium or from acquired defects in the epithelial absorptive surface. Another factor that can interfere with nutrient absorption is maldigestion, which is due to impaired digestion of nutrients within the intestinal lumen or at the terminal digestive site of the brush border membrane of mucosal epithelial cells.",
"   </p>",
"   <p>",
"    Although malabsorption and maldigestion are pathophysiologically different, the processes underlying digestion and absorption are interdependent. As a result, in clinical practice the term malabsorption has come to denote derangements in both processes.",
"   </p>",
"   <p>",
"    Three steps are required for normal nutrient absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Luminal and brush border processing",
"     </li>",
"     <li>",
"      Absorption into the intestinal mucosa",
"     </li>",
"     <li>",
"      Transport into the circulation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malabsorption can result from defects in each of these three phases (",
"    <a class=\"graphic graphic_table graphicRef54743 \" href=\"mobipreview.htm?5/6/5229\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, one or more mechanisms may exist concurrently. Thus, while the clinical sequelae may be similar for two causes of malabsorption, the underlying pathophysiology and treatment may be very different.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of malabsorption will be reviewed here. The pathophysiology of malabsorption and the individual disorders causing malabsorption (eg, celiac disease, chronic pancreatitis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency) and an overview of the treatment of malabsorption are discussed separately in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41765?source=see_link\">",
"     \"Mechanisms of nutrient absorption and malabsorption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=see_link\">",
"     \"Overview of the treatment of malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) guideline for chronic diarrhea (including a discussion on malabsorption) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/2\">",
"     2",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    . An approach to patients with suspected malabsorption was also proposed in a guideline issued by the World Organisation of Gastroenterology (",
"    <a class=\"external\" href=\"file://www.omge.org/globalguidelines/guide03/guideline3.htm\">",
"     www.omge.org/globalguidelines/guide03/guideline3.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of malabsorption depend upon the cause and severity of the disease (",
"    <a class=\"graphic graphic_table graphicRef76166 \" href=\"mobipreview.htm?22/44/23244\">",
"     table 2",
"    </a>",
"    ). Malabsorption may either be global or partial (isolated).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Global malabsorption results from diseases associated with either diffuse mucosal involvement or a reduced absorptive surface. An example is celiac disease in which diffuse mucosal disease can lead to impaired absorption of almost all nutrients.",
"      <br/>",
"      <br/>",
"      The classic manifestations of global malabsorption are diarrhea with pale, greasy, voluminous, foul-smelling stools and weight loss despite adequate food intake. However, this spectrum of findings is relatively uncommon, even with generalized mucosal disease. The majority of patients have relatively mild gastrointestinal symptoms, which often mimic more common disorders such as irritable bowel syndrome. In some cases, anorexia, flatulence, abdominal distension and borborygmi may be the only complaints suggesting malabsorption; other patients may be asymptomatic. Clinical manifestations related to a specific micronutrient deficiency can predominate in some patients. As an example, iron deficiency anemia or osteopenia may be the only clue to the presence of celiac disease in some patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Partial or isolated malabsorption results from diseases that interfere with the absorption of specific nutrients. Defective cobalamin absorption, for example, can be seen in patients with pernicious anemia or those with disease (or resection) of the terminal ileum such as patients with Crohn's disease.",
"      <br/>",
"      <br/>",
"      Isolated forms of malabsorption may present solely with symptoms that are attributable to the particular nutrient in question (",
"      <a class=\"graphic graphic_table graphicRef53852 \" href=\"mobipreview.htm?20/26/20907\">",
"       table 3",
"      </a>",
"      ). Thus, the only evidence of malabsorption may be a low serum concentration of vitamin B12 in patients who have pernicious anemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of malabsorption can often be obtained from a detailed patient history, which can also exclude other causes of symptoms. As an example, a history of intestinal resection or chronic pancreatitis may suggest the diagnosis in patients with characteristic symptoms (",
"    <a class=\"graphic graphic_table graphicRef59713 \" href=\"mobipreview.htm?33/11/33979\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because symptoms may be absent or mimic other diseases, a routine battery of blood tests is often helpful as an initial step when malabsorption is suspected. Blood tests alone cannot establish a diagnosis of malabsorption but can provide supportive evidence. Furthermore, deficiencies of specific nutrients and vitamins may point towards the underlying cause and its duration (",
"    <a class=\"graphic graphic_table graphicRef76166 \" href=\"mobipreview.htm?22/44/23244\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several invasive and noninvasive tests are available to establish the cause of malabsorption. The malabsorption of fat is the most commonly used indicator of global malabsorption for two reasons: (1) among the macronutrients (fat, carbohydrates, and protein), the process by which fat is absorbed is the most complex and, therefore, it tends to be the most sensitive to interference from disease processes; and (2) it is the most calorically dense macronutrient and, therefore, its malabsorption is a critical factor in the weight loss that often accompanies malabsorptive disorders. If the history suggests a particular cause, testing can be directed to confirm the diagnosis. Further testing may not be necessary in patients who have gross steatorrhea (increased fecal fat excretion) with an obvious cause (such as cystic fibrosis or short bowel syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link\">",
"     \"Chronic complications of the short bowel syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The order of testing and choice of a particular test should be individualized while considering the availability and expertise needed for specialized testing. While many tests are established as gold standards for the diagnosis of particular forms of malabsorption, new tests continue to be developed and their diagnostic characteristics remain uncertain.",
"   </p>",
"   <p>",
"    Thus, optimal strategies for diagnosis are still evolving. An approach to patients with suspected malabsorption was proposed in a guideline issued by the World Organisation of Gastroenterology (",
"    <a class=\"external\" href=\"file://www.omge.org/globalguidelines/guide03/guideline3.htm\">",
"     www.omge.org/globalguidelines/guide03/guideline3.htm",
"    </a>",
"    ). Our general approach is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We obtain an assessment of stool fat. As a general rule, we begin with a qualitative assessment of fecal fat on a single specimen since it is easier to perform. We proceed with a quantitative assessment of a 72 hour stool collection on a 100 gram",
"      <span class=\"nowrap\">",
"       fat/day",
"      </span>",
"      diet if the qualitative is negative and clinical suspicion remains high. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fecal fat determination'",
"      </a>",
"      below.) In those with increased fecal fat, we proceed with serologic testing for celiac disease and fecal elastase determination to exclude maldigestion due to pancreatic insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34201?source=see_link\">",
"       \"Pancreatic exocrine function tests\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We also obtain an abdominal ultrasound, which can help in identifying intestinal wall thickening (such as in Crohn's disease) or dilation of jejunal loops (such as in celiac disease). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32154?source=see_link\">",
"       \"Transabdominal ultrasonography of the small and large intestine\"",
"      </a>",
"      .) Abdominal ultrasonography of the small and large intestine is not used commonly in the United States where a small bowel follow-through, abdominal computed tomography (CT) scan, magnetic resonance enterography, or endoscopy tends to be preferred as the initial imaging modality.",
"     </li>",
"     <li>",
"      We perform a colonoscopy with intubation of the terminal ileum. A sigmoidoscopy may be sufficient in younger patients (&lt;45) since the yield is similar to colonoscopy (except if Crohn's disease is suspected). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=see_link\">",
"       \"Approach to the adult with chronic diarrhea in developed countries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14089?source=see_link\">",
"       \"Endoscopic diagnosis of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We obtain additional testing if a specific cause is obtained on the history or physical examination. By contrast, further testing may not be needed in patients who have gross steatorrhea with an obvious cause (such as cystic fibrosis or short bowel syndrome). Nevertheless, when evaluating diarrhea in short bowel syndrome, it is particularly important to perform sufficient diagnostic tests to distinguish between diarrhea arising from fat malabsorption (steatorrhea) and diarrhea arising from the malabsorption of bile acids, since the management of these two conditions is diametrically opposite in many respects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, evaluation of malabsorption begins with endoscopy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Endoscopy and pancreatic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gross morphologic appearance on upper gastrointestinal endoscopy may suggest the presence of malabsorption but an intestinal biopsy provides the essential diagnostic information. A cobblestone appearance of the duodenal mucosa is seen in Crohn's disease, while reduced duodenal folds and scalloping of the mucosa (",
"    <a class=\"graphic graphic_picture graphicRef65969 \" href=\"mobipreview.htm?11/1/11281\">",
"     picture 1",
"    </a>",
"    ) may be evident in celiac disease. The unusual finding of multiple jejunal ulcers may indicate the presence of jejunoileitis or lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/4\">",
"     4",
"    </a>",
"    ]. Use of vital dyes may be helpful in evaluating patients with celiac disease with partial villous atrophy since the abnormalities can be patchy and the duodenum may appear normal during standard endoscopy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/10/15522?source=see_link\">",
"     Indigo carmine",
"    </a>",
"    dye spraying is more accurate for identifying patients with partial atrophy than standard endoscopy (91 versus 9 percent in one series), and is also useful for directing biopsies in patients with patchy villous atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small bowel biopsy is safe and can help establish the diagnosis. Tissue should be obtained distal to the ampulla of Vater using biopsy forceps passed through a gastroduodenoscope or enteroscope. Obtaining four biopsies at different sites optimizes the likelihood of obtaining a diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Imaging of the pancreas by CT, endoscopic retrograde cholangiopancreatography (ERCP), magnetic resonance cholangiopancreatography (MRCP), or ultrasonography may be helpful in the diagnosis of chronic pancreatitis and may be critical for distinguishing benign from malignant causes. Sequential dilation and sacculation of the pancreatic duct are pathognomonic of chronic pancreatitis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62322 \" href=\"mobipreview.htm?9/31/9727\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    .) ERCP may permit therapeutic options in patients with chronic pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=see_link\">",
"     \"Treatment of chronic pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a normal ERCP does not exclude the presence of pancreatic exocrine insufficiency. Direct pancreatic intubation tests, such as the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation test, still constitute the most sensitive means of diagnosing pancreatic insufficiency in centers in which it is performed accurately (sensitivity and specificity of approximately 80 to 90 percent). The test involves intubation of the duodenum and the collection of pancreatic juices after intravenous secretin injection (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Tests for pancreatic insufficiency'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Barium studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An upper gastrointestinal series with small bowel follow-through or enteroclysis (a double contrast study performed by passing a tube into the proximal small bowel and injecting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/28/29123?source=see_link\">",
"     methylcellulose",
"    </a>",
"    ) can provide important information about the gross morphology of the small intestine. As an example, identification of small bowel diverticula and other anatomic abnormalities associated with bacterial overgrowth is best achieved with barium studies. Barium studies can also identify mucosal diseases that are not easily accessible by endoscopy. Although it is generally accepted that the radiologic findings in malabsorption are nonspecific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/7\">",
"     7",
"    </a>",
"    ], barium studies can be effective at identifying the disease process responsible for the malabsorption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Wireless capsule endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wireless capsule endoscopy allows for visualization of the entire small bowel and allows for much more detailed evaluation of small bowel mucosal disease than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    studies. Thus, it may have a role in evaluating suspected small bowel disease (such as Crohn's disease) associated with malabsorption. Because of the risk of retention, wireless capsule endoscopy should generally be avoided in patients with known or suspected small bowel strictures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17178?source=see_link\">",
"     \"Wireless video capsule endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TESTS FOR FAT MALABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tests can be used to detect fat malabsorption (steatorrhea). Currently, the gold standard for diagnosis of steatorrhea is quantitative measurement of stool fat via a traditional biochemical assay. Alternative methods of quantitating excess fat in the stool exist, such as near-infrared reflectance analysis and the acid steatocrit. The near-infrared analysis is the most accurate: its concordance with the biochemical method generally has a correlation coefficient exceeding 0.85-0.90 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fecal fat determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In healthy people, daily fecal fat excretion is less than 6 g and remains constant even if fat consumption is increased to 100 to 125 g of",
"    <span class=\"nowrap\">",
"     fat/day.",
"    </span>",
"    However, fecal fat excretion can be moderately increased in diarrheal diseases even without fat malabsorption. Values of up to 14",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    have been reported in volunteers in whom diarrhea was intentionally induced and in patients with a stool weight of greater than 1000",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, a modest increase in fecal fat excretion in a patient with diarrhea does not necessarily indicate malabsorption as the primary cause and other tests should be performed to identify the cause of the diarrhea.",
"   </p>",
"   <p>",
"    A three- to five-day collection is ideal because it reduces errors and variability that may occur if a shorter collection period is used. A longer collection period also allows the estimation of daily stool weight, which is usually greater than 200",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in patients with steatorrhea. Patients should consume 70 to 120",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of dietary fat for accurate determination (normal elderly patients may have excessive stool fat if they ingest more than 140 g fat per day). They should be instructed to avoid nonabsorbable fat substitutes, such as olestra, which can lead to false positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/10\">",
"     10",
"    </a>",
"    ]. More than 6",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    of fat in stool is pathologic, although patients with steatorrhea usually have more than 20",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"   </p>",
"   <p>",
"    Keeping a record of all dietary intake beginning the day before, and extending for the remainder of the stool collection, improves the interpretation of the test. Average daily fat intake can then be easily determined, from which the percent of fat absorbed (\"fractional fat absorption\") can be calculated: &gt;94 percent is normal. Fractional fat absorption is equal to (fat intake minus fat output) divided by fat intake. This is a more precise way of interpreting the test. Importantly, quantitative fecal fat determination does not discriminate between causes of steatorrhea, as there may be considerable overlap in values.",
"   </p>",
"   <p>",
"    A number of other tests that can be performed more easily and more quickly than a 72-hour fecal fat determination have been evaluated for the diagnosis of malabsorption. None has yet replaced the 72-hour collection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sudan III stain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because a 72-hour stool collection is cumbersome, qualitative tests continue to be used in the clinic. The Sudan III stain and acid steatocrit are examples. If properly performed, a Sudan stain on a spot sample of stool can detect more than 90 percent of patients with clinically significant steatorrhea. One group suggested that counting and measuring the size of fat globules present in stool improved the accuracy of the assay while allowing for quantitative evaluation of the data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/11\">",
"     11",
"    </a>",
"    ]. Nevertheless, variability in the performance and interpretation of the test limit its overall sensitivity and reliability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/12\">",
"     12",
"    </a>",
"    ]. \"Neutral\" versus \"split\" fecal fat can be determined after the stool samples are stained with Sudan III before and after acidification and heating: neutral fat will be stained under basal conditions, and split fat will stain after acidification and heating. Such a distinction, however, is not a valid method of distinguishing maldigestion versus malabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Near infrared reflectance analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel method, near infrared reflectance analysis (NIRA) may become the procedure of choice for evaluating fat malabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ]. NIRA is equally accurate but less time-consuming than a 72-hour fecal fat collection, and allows for simultaneous measurement of fecal fat, nitrogen, and carbohydrates in a single sample. NIRA is being increasingly used in Europe and is also available in some centers in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Acid steatocrit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acid steatocrit (a gravimetric assay performed on a spot stool sample) may provide an accurate and simplified method for detecting steatorrhea on a spot stool specimen. A study evaluating this technique found a sensitivity of 100 percent, specificity of 95 percent and positive predictive value of 90 percent compared to a 72-hour fecal fat collection as the gold standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     14C-triolein breath test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another test for fat malabsorption is the 14C-triolein breath test. The test involves measurement of breath CO2 after ingestion of the radiolabeled triglyceride triolein, and provides a measure of fat absorption. However, interpretation of results is difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/17,18\">",
"     17,18",
"    </a>",
"    ] because it has limited sensitivity in detecting minor or moderate degrees of malabsorption, several common disease states can lead to erroneous values, and normal values are affected by aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/18\">",
"     18",
"    </a>",
"    ]. As a result, the test has little utility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TESTS FOR CARBOHYDRATE MALABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, tests for carbohydrate malabsorption rely upon the fermentation of undigested carbohydrates by intestinal bacteria, or direct measurement of the absorption of specific nutrients after a test dose. Examples are the lactose tolerance test as well as several breath tests, which measure hydrogen or radioactive isotopes from sugars containing radionuclide carbon analogues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     D-xylose test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The D-xylose test measures the absorptive capacity of the proximal small intestine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/19\">",
"     19",
"    </a>",
"    ] and is used to determine whether defects in the intestinal epithelium are responsible for malabsorption. D-xylose is a pentose monosaccharide that can be absorbed both by an active sodium transporter and by passive diffusion. The dose used in testing is generally able to be absorbed by passive diffusion. Thus, the test is a measure of the permeability of the proximal small intestine, rather than a specific defect in D-xylose absorption.",
"   </p>",
"   <p>",
"    Following an overnight fast, the patient ingests a 25 g dose of D-xylose, and urine is collected for the next five hours. A venous blood sample is also collected after one hour. Normal excretion of D-xylose is 6.0",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    1.5 g (the lower limit of normal in individuals &gt;65 is 3.5 g). Excretion of lesser amounts of D-xylose or a serum D-xylose concentration less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    suggests abnormal absorption. Low blood levels and urinary excretion suggests mucosal disease such as celiac sprue. Absorption is usually normal in pancreatic insufficiency since pancreatic enzymes are not required for xylose absorption.",
"   </p>",
"   <p>",
"    Although it remains a useful test, one should remain mindful that several conditions may lead to false positive results. The presence of renal dysfunction or an inadequate urine sample is associated with falsely depressed urinary values of D-xylose although serum values should still be normal. This may occur in some older patients (those older than 65) due to a decrease in the glomerular filtration rate associated with aging. False positive results can also be seen with impaired gastric emptying, ascites, urinary retention, or fermentation of D-xylose by intestinal bacteria in patients with bacterial overgrowth. In addition, drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    diminish urinary excretion of D-xylose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lactose tolerance test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lactose tolerance test can easily diagnose lactose intolerance. Following oral administration of a 50 g test dose, blood glucose levels are monitored at 0, 60, and 120 minutes. An increase in blood glucose by less than 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    plus the development of symptoms is diagnostic. False negative results can occur in patients with diabetes or bacterial overgrowth. Abnormal gastric emptying may also lead to spurious results as blood glucose may be relatively higher with rapid and artificially depressed with delayed gastric emptying.",
"   </p>",
"   <p>",
"    Another form of the test is measurement of breath hydrogen following lactose challenge. An increase in breath hydrogen by more than 20 ppm is diagnostic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link\">",
"     \"Lactose intolerance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Breath tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breath tests using H2 or (13)CO2 can be used to diagnose specific forms of carbohydrate malabsorption (eg, lactose, fructose, sucrose isomaltase and others). Combined with serial determinations of D-xylose absorption, these tests can also monitor patients during treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. A discrepancy between hydrogen and 13C-lactose breath tests may be seen in as many of one-third of patients because the excretion of 13CO2 can be influenced by colonic gas production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/24\">",
"     24",
"    </a>",
"    ]. A combined",
"    <span class=\"nowrap\">",
"     H2/13CO2",
"    </span>",
"    lactose breath test may be more sensitive than either of these tests alone. Measurement of breath methane may enhance the accuracy of breath hydrogen testing, but has not reached broad use in routine clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. All of these breath tests rely on bacterial fermentation of nonabsorbed carbohydrate and therefore concurrent antibiotic administration often alters the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PROTEIN MALABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine testing for protein malabsorption is generally not performed in the clinic setting. The tests are technically difficult and intestinal protein loss is more commonly a result of either bacterial overgrowth or protein losing gastroenteropathy. Enteral protein loss should be directly demonstrable by measurement of the alpha-1 antitrypsin clearance. In massive enteral protein loss, the exact site of protein leakage may be localized by the infusion of 99mTc-albumin and gamma camera scintigraphy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma citrulline and arginine concentrations are highly correlated to small bowel length [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/27\">",
"     27",
"    </a>",
"    ]. In patients with short bowel syndrome, postabsorptive plasma citrulline determination can be used to estimate functional absorptive bowel length and help determine the likelihood of permanent intestinal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADDITIONAL TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional tests are used to assess small bowel function, bile acid absorption, and pancreatic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Schilling test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Schilling test identifies the cause of vitamin B12 malabsorption (",
"    <a class=\"graphic graphic_figure graphicRef72051 \" href=\"mobipreview.htm?22/29/22994\">",
"     figure 1",
"    </a>",
"    ). However, it is rarely performed given the availability of serum B12 and methylmalonic acid to diagnose B12 deficiency and the easy use of oral crystalline or parenteral injection of B12. Nevertheless, there may be occasional patients in whom it can be informative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vitamin B12 is absorbed by specialized receptors in the terminal ileum. Absorption depends upon the presence of intrinsic factor, and can be reduced by chronic atrophic gastritis, small intestinal bacterial overgrowth, exocrine pancreatic insufficiency, and ileal disease. Part one of the Schilling test involves administration of radiolabeled B12 alone; part two involves the addition of intrinsic factor, and part three involves administration of antibiotics prior to part two. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal absorption after the addition of intrinsic factor (and after the exclusion of small intestinal bacterial overgrowth), suggests terminal ileal disease. Small intestinal bacterial overgrowth is suggested if an abnormal test is normalized after a therapeutic trial with antibiotics. The Schilling test can also be abnormal in pancreatic insufficiency and celiac disease. Normalization after pancreatic enzyme substitution or a gluten-free diet is useful for diagnosis of these causes of malabsorption (",
"    <a class=\"graphic graphic_table graphicRef62166 \" href=\"mobipreview.htm?7/10/7340\">",
"     table 5",
"    </a>",
"    ). The Schilling test can also be used to determine the restoration of the functional integrity of the ileal mucosa after treatment of ileal Crohn's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     SeHCAT test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile acid malabsorption most often occurs when more than 100 cm of terminal ileum has been removed but can also result from disease of the terminal ileum (usually Crohn's disease), HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], or primary abnormalities in bile acid absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. It has been proposed that primary bile salt malabsorption may reflect impaired fibroblast growth factor 19 feedback inhibition causing excessive bile acid synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/32\">",
"     32",
"    </a>",
"    ]. An association with gallbladder dysfunction (Habba syndrome) has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/33\">",
"     33",
"    </a>",
"    ]. Presentation of the excess bile salts to the colon can lead to diarrhea (called cholerheic enteropathy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30601?source=see_link\">",
"     \"Pathophysiology of the short bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with diarrhea in association with terminal ileal resection are often treated with a bile acid binding resin such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    . Such a therapeutic trial will often be effective if the extent of resection (or disease) is not so large as to cause steatorrhea. If this is ineffective, or in patients with terminal ileal disease in whom the diarrhea does not respond to conventional antidiarrheal or anti-Crohn's therapy, objective evidence of cholerheic enteropathy can be established by the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    homocholic acid taurine (75SeHCAT) test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The SeHCAT test involves the administration of a selenium75 labeled synthetic bile acid (selen-homotaurocholic acid) orally, followed by measurement of retention of the bile acid by whole body scan or gamma camera at seven days (abnormal is less than 5 percent).",
"   </p>",
"   <p>",
"    However, the SeHCAT test is not used commonly. Quantitative measurement of bile acids in stool in patients who did not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    may be the method of choice to diagnose cholerheic enteropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Tests for bacterial overgrowth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for diagnosis of bacterial overgrowth is the direct quantitative measurement of bacterial counts from aspirated intestinal fluid. Normal counts rarely exceed",
"    <span class=\"nowrap\">",
"     10(4)/mL",
"    </span>",
"    in the jejunum and",
"    <span class=\"nowrap\">",
"     10(5)/mL",
"    </span>",
"    in the ileum. However, direct estimation of bacterial counts in the gut requires intubation of the intestine and careful technique to avoid contamination from oral or nasal sources [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/37\">",
"     37",
"    </a>",
"    ]. As a result, hydrogen breath tests with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    or other carbohydrate substrates have replaced bacterial cultures for the diagnosis of small bowel bacterial overgrowth. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=see_link\">",
"     \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Tests for pancreatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several invasive and noninvasive tests are available for the diagnosis of pancreatic insufficiency, which can be classified as direct or indirect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34201?source=see_link\">",
"     \"Pancreatic exocrine function tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traditionally, direct tests involve the stimulation of the pancreas through the administration of a meal or hormonal secretagogues after which duodenal fluid is collected and analyzed to quantify normal pancreatic secretory content (ie, enzymes, and bicarbonate). Only a few specialized centers perform these tests. A much simpler direct test is measurement of fecal elastase-1. In mild insufficiency, the latter lacks some of the sensitivity possessed by more traditional testing, but it is accurate in moderate to severe insufficiency and its simplicity and convenience make it a useful test [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38232/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Indirect tests measure the consequences of pancreatic insufficiency and are more widely available. However, they depend upon the consequences of pancreatic maldigestion, which are generally not apparent until normal enzyme secretory output has declined by more than 90 percent. Thus, they are insensitive to early pancreatic insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical features of malabsorption depend upon the cause and severity of the disease (",
"      <a class=\"graphic graphic_table graphicRef76166 \" href=\"mobipreview.htm?22/44/23244\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology can often be obtained from a detailed patient history, which can also exclude other causes of symptoms. As an example, a history of intestinal resection or chronic pancreatitis may suggest the diagnosis in patients with characteristic symptoms (",
"      <a class=\"graphic graphic_table graphicRef59713 \" href=\"mobipreview.htm?33/11/33979\">",
"       table 4",
"      </a>",
"      ). Deficiencies of specific nutrients and vitamins may also identify the underlying cause and its duration (",
"      <a class=\"graphic graphic_table graphicRef76166 \" href=\"mobipreview.htm?22/44/23244\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because symptoms may be absent or mimic other diseases, a routine battery of blood tests is often helpful as an initial step when malabsorption is suspected, although blood tests alone should not be considered as being sufficient to establish a diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several invasive and noninvasive tests are available to establish the cause of malabsorption. If the history suggests a particular cause, testing can be directed to confirm the diagnosis. Further testing may not be necessary in patients who have gross steatorrhea (increased fecal fat excretion) with an obvious cause (such as cystic fibrosis or short bowel syndrome). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The order of testing and choice of a particular test should be individualized while considering the availability and expertise needed for specialized testing. While many tests are established as gold standards for the diagnosis of particular forms of malabsorption, new tests continue to be developed and their diagnostic characteristics remain uncertain. Thus, optimal strategies for diagnosis are still evolving. Our approach is described above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Hogenauer C, Hammer H. Maldigestion and Malabsorption. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 9th ed, Feldman M, Friedman L, Brandt L (Eds), Saunders, Philadelphia, PA 2010. p.1735-1768.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/2\">",
"      American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/3\">",
"      Mustalahti K, Collin P, Siev&auml;nen H, et al. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/4\">",
"      Widjaja A, Wagner S, Mix H, et al. Malabsorption with progressive weight loss and multiple intestinal ulcers in a patient with T-cell lymphoma. Z Gastroenterol 1999; 37:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/5\">",
"      Siegel LM, Stevens PD, Lightdale CJ, et al. Combined magnification endoscopy with chromoendoscopy in the evaluation of patients with suspected malabsorption. Gastrointest Endosc 1997; 46:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/6\">",
"      Tischendorf JJ, Wopp K, Streetz KL, et al. [The value of duodenal biopsy within routine upper endoscopy: a prospective study in 1000 patients]. Z Gastroenterol 2008; 46:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/7\">",
"      Maglinte DD, Kelvin FM, O'Connor K, et al. Current status of small bowel radiography. Abdom Imaging 1996; 21:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/8\">",
"      Neumeister V, Henker J, Kaltenborn G, et al. Simultaneous determination of fecal fat, nitrogen, and water by near-infrared reflectance spectroscopy. J Pediatr Gastroenterol Nutr 1997; 25:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/9\">",
"      Fine KD, Fordtran JS. The effect of diarrhea on fecal fat excretion. Gastroenterology 1992; 102:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/10\">",
"      Balasekaran R, Porter JL, Santa Ana CA, Fordtran JS. Positive results on tests for steatorrhea in persons consuming olestra potato chips. Ann Intern Med 2000; 132:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/11\">",
"      Fine KD, Ogunji F. A new method of quantitative fecal fat microscopy and its correlation with chemically measured fecal fat output. Am J Clin Pathol 2000; 113:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/12\">",
"      Simko V. Fecal fat microscopy. Acceptable predictive value in screening for steatorrhea. Am J Gastroenterol 1981; 75:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/13\">",
"      Khouri MR, Ng SN, Huang G, Shiau YF. Fecal triglyceride excretion is not excessive in pancreatic insufficiency. Gastroenterology 1989; 96:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/14\">",
"      Stein J, Purschian B, Zeuzem S, et al. Quantification of fecal carbohydrates by near-infrared reflectance analysis. Clin Chem 1996; 42:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/15\">",
"      Bekers O, Postma C, Fischer JC, et al. Faecal nitrogen determination by near-infrared spectroscopy. Eur J Clin Chem Clin Biochem 1996; 34:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/16\">",
"      Amann ST, Josephson SA, Toskes PP. Acid steatocrit: a simple, rapid gravimetric method to determine steatorrhea. Am J Gastroenterol 1997; 92:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/17\">",
"      Mylvaganam K, Hudson PR, Ross A, Williams CP. 14C triolein breath test: a routine test in the gastroenterology clinic? Gut 1986; 27:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/18\">",
"      Mylvaganam K, Hudson PR, Herring A, Williams CP. 14C triolein breath test: an assessment in the elderly. Gut 1989; 30:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/19\">",
"      Peled Y, Doron O, Laufer H, et al. D-xylose absorption test. Urine or blood? Dig Dis Sci 1991; 36:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/20\">",
"      Casellas F, Chicharro L, Malagelada JR. Potential usefulness of hydrogen breath test with D-xylose in clinical management of intestinal malabsorption. Dig Dis Sci 1993; 38:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/21\">",
"      Casellas F, Malagelada JR. Clinical applicability of shortened D-xylose breath test for diagnosis of intestinal malabsorption. Dig Dis Sci 1994; 39:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/22\">",
"      Carlson S, Craig RM. D-xylose hydrogen breath tests compared to absorption kinetics in human patients with and without malabsorption. Dig Dis Sci 1995; 40:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/23\">",
"      Choi YK, Johlin FC Jr, Summers RW, et al. Fructose intolerance: an under-recognized problem. Am J Gastroenterol 2003; 98:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/24\">",
"      Koetse HA, Vonk RJ, Pasterkamp S, et al. Variations in colonic H2 and CO2 production as a cause of inadequate diagnosis of carbohydrate maldigestion in breath tests. Scand J Gastroenterol 2000; 35:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/25\">",
"      Rumessen JJ, Nordgaard-Andersen I, Gudmand-H&oslash;yer E. Carbohydrate malabsorption: quantification by methane and hydrogen breath tests. Scand J Gastroenterol 1994; 29:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/26\">",
"      Corazza GR, Benati G, Strocchi A, et al. The possible role of breath methane measurement in detecting carbohydrate malabsorption. J Lab Clin Med 1994; 124:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/27\">",
"      Crenn P, Coudray-Lucas C, Thuillier F, et al. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000; 119:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/28\">",
"      Steuerwald M, Bucher HC, M&uuml;ller-Brand J, et al. HIV-enteropathy and bile acid malabsorption: response to cholestyramine. Am J Gastroenterol 1995; 90:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/29\">",
"      Koch J, Garcia-Shelton YL, Neal EA, et al. Steatorrhea: a common manifestation in patients with HIV/AIDS. Nutrition 1996; 12:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/30\">",
"      Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/31\">",
"      Popovi OS, Kosti KM, Milovi VB, et al. Primary bile acid malabsorption. Histologic and immunologic study in three patients. Gastroenterology 1987; 92:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/32\">",
"      Walters JR, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009; 7:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/33\">",
"      Habba SF. Chronic diarrhea: identifying a new syndrome. Am J Gastroenterol 2000; 95:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/34\">",
"      Merrick MV. Gall-bladder and colonic retention of SeHCAT: a re-evaluation. Eur J Nucl Med 1994; 21:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/35\">",
"      Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut 1994; 35:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/36\">",
"      Wildt S, N&oslash;rby Rasmussen S, Lysg&aring;rd Madsen J, Rumessen JJ. Bile acid malabsorption in patients with chronic diarrhoea: clinical value of SeHCAT test. Scand J Gastroenterol 2003; 38:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/37\">",
"      Rubio-Tapia A, Barton SH, Rosenblatt JE, Murray JA. Prevalence of small intestine bacterial overgrowth diagnosed by quantitative culture of intestinal aspirate in celiac disease. J Clin Gastroenterol 2009; 43:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38232/abstract/38\">",
"      Leeds JS, Oppong K, Sanders DS. The role of fecal elastase-1 in detecting exocrine pancreatic disease. Nat Rev Gastroenterol Hepatol 2011; 8:405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4780 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38232=[""].join("\n");
var outline_f37_21_38232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Imaging tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Endoscopy and pancreatic imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Barium studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Wireless capsule endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TESTS FOR FAT MALABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fecal fat determination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sudan III stain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Near infrared reflectance analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Acid steatocrit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - 14C-triolein breath test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TESTS FOR CARBOHYDRATE MALABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      D-xylose test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lactose tolerance test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Breath tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PROTEIN MALABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADDITIONAL TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Schilling test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SeHCAT test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Tests for bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Tests for pancreatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4780\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4780|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/31/9727\" title=\"diagnostic image 1\">",
"      ERCP in chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4780|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/29/22994\" title=\"figure 1\">",
"      The Schilling test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4780|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/1/11281\" title=\"picture 1\">",
"      Celiac disease Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4780|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/6/5229\" title=\"table 1\">",
"      Mechanisms of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/44/23244\" title=\"table 2\">",
"      Clinical features malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/26/20907\" title=\"table 3\">",
"      Lab features in malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/11/33979\" title=\"table 4\">",
"      Diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/10/7340\" title=\"table 5\">",
"      Schilling test variations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/37/18007?source=related_link\">",
"      Chronic complications of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41765?source=related_link\">",
"      Mechanisms of nutrient absorption and malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/48/22279?source=related_link\">",
"      Overview of the treatment of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/25/34201?source=related_link\">",
"      Pancreatic exocrine function tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30601?source=related_link\">",
"      Pathophysiology of the short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/25/32154?source=related_link\">",
"      Transabdominal ultrasonography of the small and large intestine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/49/17178?source=related_link\">",
"      Wireless video capsule endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38233="Poor weight gain in children older than two years of age";
var content_f37_21_38233=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Poor weight gain in children older than two years of age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38233/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/21/38233/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, poor weight gain in preschool and school-age children is the consequence of inadequate dietary nutrient intake relative to metabolic and growth needs. The challenge for the child's clinician is to determine if inadequate dietary intake is the result of an underlying medical problem (organic disease), environmental or psychosocial problems, or a combination of these factors.",
"   </p>",
"   <p>",
"    This topic will discuss the etiology and approach to poor weight gain in children older than two years. Poor weight gain in children younger than two years and short stature are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14538?source=see_link\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30985?source=see_link\">",
"     \"Management of failure to thrive (undernutrition) in children younger than two years\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nutritional requirements for adolescents and vegetarian children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23735?source=see_link\">",
"     \"Dietary energy requirements in adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=see_link\">",
"     \"Vegetarian diets for children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain follows a predictable course from infancy through adolescence. Height and weight should be assessed routinely and compared with antecedent measurements.",
"   </p>",
"   <p>",
"    Whenever significant voluntary or involuntary weight loss occurs as described below, or when the rate of weight gain varies from the previously established pattern, there is cause for concern. Any deviation in the pattern of weight gain, when compared with the standardized growth curves from the National Center for Health Statistics (NCHS,",
"    <a class=\"external\" href=\"file://www.cdc.gov/growthcharts\">",
"     www.cdc.gov/growthcharts",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_figure graphicRef71721 graphicRef53325 \" href=\"mobipreview.htm?10/51/11064\">",
"     figure 1A-B",
"    </a>",
"    ) should be evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor weight gain refers to two types of growth failure in the preschool and school-age child:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abrupt weight loss following a period of normal growth along a well-established pattern of height and weight gain.",
"     </li>",
"     <li>",
"      Slow, albeit steady, weight gain that tracks along a growth channel either well below the fifth percentile of the NCHS growth curves (",
"      <a class=\"graphic graphic_figure graphicRef71721 graphicRef53325 \" href=\"mobipreview.htm?10/51/11064\">",
"       figure 1A-B",
"      </a>",
"      ) or a growth curve proportionate to, but lower than, the child's expected height trajectory (",
"      <a class=\"graphic graphic_figure graphicRef63399 graphicRef77249 \" href=\"mobipreview.htm?43/30/44519\">",
"       figure 2A-B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In either case, the definition of poor weight gain relies on the availability of serial weight measurements over a 6- to 12-month period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor weight gain is a common concern in pediatric practice. However, the precise frequency is unknown, since poor weight gain may be both over- and underdiagnosed. The parents' level of concern regarding their child's weight gain may reflect expectations based upon the parents' recollections of their own patterns of growth, whereas clinicians may have limited concerns about a child's gradual decline or slow gain in weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary cause of poor weight gain in preschool and school-age children and adolescents is inadequate dietary intake relative to metabolic and growth needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/1\">",
"     1",
"    </a>",
"    ]. The etiology of inadequate dietary intake often is mixed; underlying medical conditions and environmental or psychosocial problems play a role. Involuntary weight loss typically implies an underlying medical problem, whereas slow weight gain is usually related to social",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental factors.",
"   </p>",
"   <p>",
"    Factors contributing to inadequate dietary intake include poverty, lack of understanding on the part of the caregivers regarding the nutritional needs of children, oromotor dysfunction, increased metabolic needs, malabsorption, increased excretory losses, and the energy cost of growth itself. When inadequate intake is related to an underlying medical condition, the gastrointestinal, cardiac, and renal systems are those most commonly involved (in decreasing order of frequency) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Limited or inappropriate intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited or inappropriate intake of food can be involuntary or deliberate. Causes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poverty",
"     </li>",
"     <li>",
"      Discomfort or pain associated with eating (eg, in children with gastroesophageal reflux, esophagitis, dental caries) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oromotor dysfunction. Problems with chewing and swallowing are common in children with central nervous system or neuromuscular disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/6\">",
"       6",
"      </a>",
"      ]. Although oral motor dysfunction is unlikely to develop anew in a child older than two years without an underlying medical condition, it may become more apparent in the older child as the medical condition changes.",
"     </li>",
"     <li>",
"      Behavioral issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Toddlers may develop a feeding aversion because of poor parent-child interactions where issues of control dominate; these dietary control issues are a frequent component of failure to thrive. Food aversion also can be a learned behavior related to sensations associated with food textures, consistencies, temperatures, or smells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children between the ages of two and five years may become picky eaters [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/8\">",
"       8",
"      </a>",
"      ]. At this age, increased exploratory activities may limit the time a child focuses on eating. Strange eating habits or limited intakes of a variety of foods and beverages generally are a temporary developmental phase and may be causally related to the normal pattern of slower growth at this age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18441?source=see_link&amp;anchor=H179339902#H179339902\">",
"       \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Feeding behaviors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other behavioral issues that can affect dietary intake include hyperactivity and attention problems (related to decreased time spent eating), as well as anorexia nervosa and bulimia nervosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link&amp;anchor=H11#H11\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Presentation and screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased appetite. Decreased appetite can occur for a variety of reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Toddlers may ingest too much juice or other non-nutritious liquid, resulting in satiation and decreased appetite for higher caloric density or more nutritious solid foods [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18441?source=see_link&amp;anchor=H17#H17\">",
"       \"Dietary recommendations for toddlers, preschool, and school-age children\", section on 'Fruits and vegetables'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with any chronic disease, including gastrointestinal, renal, cardiac, or pulmonary conditions may have anorexia, vomiting, early satiety, abdominal pain, constipation, or diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Medications (eg, for seizures or attention deficit disorder) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Stressful psychosocial conditions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dietary restriction. Older children and adolescents may impose limits on their dietary intake in an effort to lose weight or be healthy. Eating disorders may develop [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Dietary restriction also may be related to actual or perceived food intolerance or allergy and cultural or personal beliefs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Restrictive diets (eg, dairy-free, vegetarian, low-fat, low-carbohydrate) may not supply all the energy and nutrient needs for a growing child or adolescent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=see_link\">",
"       \"Vegetarian diets for children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Child abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link&amp;anchor=H21#H21\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Starvation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=see_link&amp;anchor=H4#H4\">",
"       \"Child neglect and emotional abuse\", section on 'Manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Increased needs",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased metabolic rates &mdash; Children with underlying medical conditions may have increased total daily energy expenditure because of increased resting metabolic rates or energy costs associated with activity or inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/20-23\">",
"       20-23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Congenital heart disease is associated with poor weight gain because of increased total daily energy expenditure in infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Although hypoxia is thought to contribute to their poor weight gain, vomiting, alterations in carbohydrate and fat metabolism, and the energy cost of physical activity may explain the higher energy needs of infants with congenital heart disease. Presumably, these factors account for poor weight gain in the toddler and older child, as well.",
"     </li>",
"     <li>",
"      Infants with chronic lung disease experience marked stress during the early stages of disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/22\">",
"       22",
"      </a>",
"      ]. If lung disease persists, toddlers and older children may have increased energy expenditure because of increased work of breathing and recurrent respiratory illnesses. Increased energy expenditure may be the consequence of physiologic stress as indicated by increased serum catecholamines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperthyroidism is associated with increased heart rate and blood pressure, but the mechanisms responsible for thyroid-hormone-controlled energy expenditure have not been elucidated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obstructive sleep apnea may be associated with increased energy expenditure because of the increased work of breathing during sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=see_link&amp;anchor=H10#H10\">",
"       \"Evaluation of suspected obstructive sleep apnea in children\", section on 'Growth'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diencephalic syndrome, a disorder associated with central nervous system tumors, is a rare cause of profound weight loss related to increased energy expenditure, but should not be overlooked [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/27-29\">",
"       27-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation &mdash; Diseases that have an inflammatory or catabolic component, such as cystic fibrosis, inflammatory bowel disease, or malignancy, may be associated with weight loss and subsequently poor weight gain. Increased inflammatory cytokines may stimulate the release of leptin, a satiety factor that leads to poor weight gain in some of these disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased activity &mdash; The fidgety, hyperactive, or \"busy\" child may expend more energy. However, this increase in physical activity is a debatable cause of poor weight gain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased losses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased losses of nutrients in the stool or urine or as a result of vomiting may occur as a consequence of several medical conditions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carbohydrate intolerance. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=see_link&amp;anchor=H3#H3\">",
"       \"Etiology of hypoglycemia in infants and children\", section on 'Disorders of carbohydrate metabolism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Protein sensitivity (allergy). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=see_link\">",
"       \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bulimia nervosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=see_link&amp;anchor=H11#H11\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Presentation and screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Celiac disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Short gut syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=see_link\">",
"       \"Chronic complications of the short bowel syndrome in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=see_link\">",
"       \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of chronic pancreatitis in children\", section on 'Malabsorption'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cystic fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic liver disease",
"     </li>",
"     <li>",
"      Diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=see_link\">",
"       \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chronic renal disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Nutrition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inborn errors of metabolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=see_link&amp;anchor=H17#H17\">",
"       \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Gastrointestinal'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal tubular acidosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17768?source=see_link\">",
"       \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17768?source=see_link&amp;anchor=H6#H6\">",
"       \"Etiology and clinical manifestations of renal tubular acidosis in infants and children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more advanced evaluation may be required if screening studies are suggestive of these disorders. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Advanced tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Energy cost of growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who have normal, as well as catch-up, growth requirements have increased energy needs. The energy cost of growth often is underestimated. Coupled with poor dietary intake, the energy cost of growth further aggravates progressive deficits in body weight prior to linear growth arrest. The daily energy cost of growth averages 5 kilocalories per gram of tissue accreted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conceptual framework for the diagnostic approach to poor weight gain depends upon the practice pattern of the clinician. The primary care clinician frequently searches for common problems that have less severe presentations, whereas the specialist seeks to diagnose or exclude uncommon disorders that have significant medical consequences.",
"   </p>",
"   <p>",
"    In either case, the usual approach is to identify the major symptoms, consider the most common categories of disease possibilities, conduct a thorough physical examination, screen for possible disease entities, begin an empiric treatment regimen, and monitor the clinical response. The pace of the evaluation should be individualized and tailored to the severity of the problem.",
"   </p>",
"   <p>",
"    Obtaining accurate serial weight and height measurements using appropriate measuring devices is essential to establish the validity of poor weight gain. It is generally necessary to monitor weight and height for at least six months before concluding that a patient has met the definition of poor weight gain. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Definition'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    During this period, the primary care clinician may rely on simple interventional strategies (eg, nutritional counseling and dietary intervention) or systematically perform a series of diagnostic tests to help determine whether the child has an underlying medical problem in addition to contributing psychosocial or environmental factors. The primary care clinician may refer the child to the specialist when advanced diagnostic studies are required. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Diagnostic evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interview process with the parent, in conjunction with casual observation of the child's behavior and social interactions between the parent and child, often provides clues about the potential contributing factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Present illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate dietary intake relative to metabolic and growth needs, regardless of the cause, is the most common reason for poor weight gain. Thus, the medical history should focus on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Problems that affect appetite",
"     </li>",
"     <li>",
"      Eating patterns and behaviors",
"     </li>",
"     <li>",
"      Chewing and swallowing difficulties",
"     </li>",
"     <li>",
"      Diagnoses that reflect poor gastrointestinal motility, such as gastroesophageal reflux or delayed gastric emptying [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diarrhea, particularly if features of malabsorption can be identified",
"     </li>",
"     <li>",
"      Constipation, in which features of fecal impaction or pronounced bloating may disturb the child's appetite",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the review of systems or other aspects of the initial evaluation suggest a problem unrelated to the gastrointestinal tract, other causes of poor weight gain should be considered (",
"    <a class=\"graphic graphic_table graphicRef57170 \" href=\"mobipreview.htm?1/13/1244\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Diet history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parental report of the child's daily dietary intake is helpful but may be inaccurate. Parental perceptions often result in over- or underestimation of intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/34\">",
"     34",
"    </a>",
"    ]. A three-day record of the child's food and beverage consumption, as well as the use of vitamin and mineral supplements, may be more informative than simple parental report if parents are able to comply with the requirements for accurate record keeping. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=see_link&amp;anchor=H8#H8\">",
"     \"Dietary history and recommended dietary intake in children\", section on 'Dietary diary'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of the child's appetite, eating schedule, and behaviors associated with meals provides insight into feeding problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/35\">",
"     35",
"    </a>",
"    ]. It is also important to ask about parental responses to the child's eating patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Past history",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perinatal &mdash; The perinatal history should include information regarding complications during the pregnancy or delivery, gestational age and birth weight, exposures to toxins (eg, alcohol, anticonvulsants) or infectious organisms in utero, the method of feeding the child during the early postnatal period, and any clinical problems during the first postnatal year.",
"     </li>",
"     <li>",
"      Growth and developmental &mdash; Important questions in the growth and developmental history include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Has the child's weight always been below the growth curve?",
"     </li>",
"     <li>",
"      Was the child gaining normally, then slowed down, or did the child have an abrupt loss of weight?",
"     </li>",
"     <li>",
"      What triggered the change in the growth pattern?",
"     </li>",
"     <li>",
"      Did the child acquire developmental milestones on schedule?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Social history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many psychosocial issues such as poverty, young parental age, depression, alcohol or drug abuse, mental illness, and violence may contribute to poor weight gain. Observing the interactions between the parent and child may offer insight into the etiology of the child's abnormal growth pattern. Families at risk for food insecurity may be identified by asking questions such as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"In the past month, was there any day when you or anyone in your family went hungry because you did not have enough money for food?\"",
"     </li>",
"     <li>",
"      &ldquo;Within the past 12 months, did you worry whether your food would run out before you got money to buy more?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Within the past 12 months, did it ever happen that the food you bought didn&rsquo;t last and you didn&rsquo;t have money to get more?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of familial growth patterns and the determination of mid-parental height may redirect concerns or provide reassurance. As an example, if the child's actual height is two growth channels below the expected mid-parental height (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/3/30769?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), further evaluation should be considered. A review of familial medical problems, especially those that might be inherited or shared, is essential. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=see_link&amp;anchor=H11#H11\">",
"     \"Normal growth patterns in infants and prepubertal children\", section on 'Predicted height'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Review of systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;The review of systems should focus on symptoms and signs of problems that can lead to limited intake, poor utilization or malabsorption of nutrients, and increased metabolic needs (",
"    <a class=\"graphic graphic_table graphicRef57170 \" href=\"mobipreview.htm?1/13/1244\">",
"     table 1",
"    </a>",
"    ). Common symptoms or signs of concern include early satiety, dental caries, difficulty chewing and swallowing, vomiting, bloating, diarrhea, and constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination of the child with poor weight gain rarely reveals classic diagnostic signs of specific clinical entities. The clinical features of poor weight gain may be limited to decreased subcutaneous fat and muscle mass. Nonetheless, it is important to look for signs of an underlying medical condition (",
"    <a class=\"graphic graphic_table graphicRef68318 \" href=\"mobipreview.htm?38/13/39133\">",
"     table 2",
"    </a>",
"    ), anatomic abnormality, nutrient deficiency, abuse or neglect, and developmental or neurologic problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Growth parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important aspect of the physical examination is the assessment of weight, height, and body mass index (BMI). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=see_link&amp;anchor=H8#H8\">",
"     \"The pediatric physical examination: General principles and standard measurements\", section on 'Weight, height, head, and chest circumference'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body weight is obtained using a calibrated, age-appropriate scale, once heavy clothing has been removed.",
"     </li>",
"     <li>",
"      Standing height is measured without shoes using the four-point stance, with an appropriate measuring device that includes a movable perpendicular head piece (",
"      <a class=\"graphic graphic_figure graphicRef56127 \" href=\"mobipreview.htm?27/45/28371\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The BMI is calculated from the weight and square of the height as follows (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=see_link\">",
"       calculator 2",
"      </a>",
"      and",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=see_link\">",
"       calculator 3",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;BMI = body weight (kg) &divide; height (meters) squared",
"   </p>",
"   <p>",
"    Weight, height, and BMI are plotted on age- and sex-appropriate growth charts (",
"    <a class=\"graphic graphic_figure graphicRef71721 graphicRef53325 \" href=\"mobipreview.htm?10/51/11064\">",
"     figure 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63399 graphicRef77249 \" href=\"mobipreview.htm?43/30/44519\">",
"     figure 2A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef60784 graphicRef68478 \" href=\"mobipreview.htm?10/0/10247\">",
"     figure 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is critical to obtain information about previous growth parameters. Single assessments of height, weight, and BMI have limited usefulness because they do not provide sufficient information to characterize the pattern of poor weight gain.",
"   </p>",
"   <p>",
"    The differential diagnosis of poor weight gain is based upon current growth measurements and the pattern of growth failure. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute weight loss, with normal height velocity, may be due to inadequate dietary intake or the onset of a new illness.",
"     </li>",
"     <li>",
"      Decreased rates of growth in height and weight are more likely due to a chronic condition.",
"     </li>",
"     <li>",
"      Normal height and weight velocities that follow the standard NCHS growth curves but are below the third to fifth percentiles may be normal or may have an endocrinologic or psychosocial etiology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;General examination findings that may provide a clue to underlying medical illness include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal breath sounds may suggest chronic lung disease (eg, cystic fibrosis)",
"     </li>",
"     <li>",
"      A cardiac murmur may suggest congenital heart disease",
"     </li>",
"     <li>",
"      Hepatomegaly with or without splenomegaly may indicate chronic liver disease",
"     </li>",
"     <li>",
"      Abdominal distention may be associated with malabsorption, small bowel bacterial overgrowth, or giardiasis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=see_link\">",
"       \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests and imaging studies are unlikely to lead to the diagnosis of an underlying medical disorder in the absence of findings from the medical history or physical examination. However, selective screening studies may provide reassurance that certain conditions are unlikely to be present.",
"   </p>",
"   <p>",
"    Laboratory tests and diagnostic imaging studies should be performed in a step-wise and focused manner. Specialized testing may be warranted if an etiology has not been found and the patient does not respond to dietary or behavior modification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Initial tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial (baseline) tests in the evaluation of poor weight gain in children older than two years may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CBC, CRP, and ESR as a screen for anemia, chronic infection, inflammation, and malignancy",
"     </li>",
"     <li>",
"      Urinalysis and culture as a screen for protein or carbohydrate loss and indolent renal disease, such as chronic urinary tract infection or renal tubular acidosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional laboratory tests or imaging studies may be necessary in the initial evaluation if the history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examination suggest particular conditions. The additional tests that may be warranted include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrolytes, BUN, creatinine, glucose, calcium, phosphorus, magnesium, albumin, total protein, liver enzymes, amylase, lipase. These should be obtained to evaluate kidney, liver, and pancreatic function; they also provide an indication of nutritional status. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22391?source=see_link&amp;anchor=H2#H2\">",
"       \"Laboratory and radiologic evaluation of nutritional status in children\", section on 'Laboratory evaluation of undernutrition'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stool for Helicobacter pylori if H. pylori disease is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link&amp;anchor=H22#H22\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\", section on 'Stool antigen assay'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stool studies including guaiac, routine culture, ova and parasite smears,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Giardia antigen if gastrointestinal infection is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stool-reducing substances, alpha-1 antitrypsin, and elastase if gastrointestinal malabsorption is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid studies if there are symptoms or signs of hyperthyroidism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Tuberculin skin testing if tuberculosis is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=see_link\">",
"       \"Latent tuberculosis infection in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=see_link\">",
"       \"Tuberculosis disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chest radiograph if cardiac or pulmonary disease is suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Advanced tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized testing may be warranted if certain diagnoses are suspected or if an etiology has not been found and the patient has not responded to dietary or behavior modification. Specialized testing may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV test. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=see_link\">",
"       \"Diagnostic assays for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Quantitative immunoglobulins, tissue transglutaminase. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease panel for Anti-Saccharomyces cerevisiae antibodies (ASCA), perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), and anti-ompC antibodies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum IgE, radioallergosorbent tests (RAST), and skin tests to selected food antigens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"       \"Clinical manifestations of food allergy: An overview\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=see_link\">",
"       \"Diagnostic evaluation of food allergy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum antinuclear antibodies (ANA), anti-endomesial antibodies, and anti-LKM antibodies as markers for autoimmune disease",
"     </li>",
"     <li>",
"      Hepatitis (A, B, C) panel. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16295?source=see_link\">",
"       \"Overview of hepatitis A virus infection in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31386?source=see_link\">",
"       \"Overview of hepatitis B virus infection in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6186?source=see_link\">",
"       \"Hepatitis C virus infection in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CMV and EBV; IgM and IgG. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/51/36664?source=see_link\">",
"       \"Cytomegalovirus infection and disease in newborns, infants, children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=see_link\">",
"       \"Clinical manifestations and treatment of Epstein-Barr virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for inborn errors of metabolism, storage diseases, or chromosomal abnormalities (eg, serum amino acids, urine organic acids, urine-reducing substances, serum",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      profile, chromosomes). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advanced endocrine evaluation, particularly growth hormone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link\">",
"       \"Diagnosis of growth hormone deficiency in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sweat chloride test. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      UGI series, small bowel follow through, swallowing function study to evaluate gastrointestinal disease.",
"     </li>",
"     <li>",
"      Advanced diagnostic imaging studies, such as abdominal ultrasound and abdominal and head CT scans, to evaluate the presence of intraabdominal and intracranial processes that may affect appetite or cause vomiting.",
"     </li>",
"     <li>",
"      Advanced endoscopic studies with biopsies, including duodenoscopy, colonoscopy, small bowel capsule enteroscopy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38233/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=see_link\">",
"       \"Acute and chronic gastritis due to Helicobacter pylori\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=see_link\">",
"       \"Clinical manifestations of peptic ulcer disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of poor weight gain in children older than two years of age depends upon the clinical findings and results of diagnostic studies. The approach to treatment often is multifaceted. The response to intervention aids in the diagnostic process.",
"   </p>",
"   <p>",
"    Hospitalization is warranted if a serious organic cause is suspected (eg, malignancy), if there is concern for neglect or abuse, or when eating patterns need to be observed. Otherwise, most cases can be handled on an outpatient basis. Any medical conditions that are discovered should be treated appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Dietary intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional counseling and dietary intervention are the first steps to therapy and should begin during the evaluation. Dietary interventions are based on increasing the intake of foods and beverages that have increased caloric density.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children can increase their dietary energy intake by supplementing foods with margarine, honey, syrups, gravies, creams, cheese, peanut butter, avocados, and ice cream",
"     </li>",
"     <li>",
"      Parents should offer the child at least three mini-meals in addition to three well-balanced meals daily",
"     </li>",
"     <li>",
"      Parents may purchase commercially available formulas and puddings to supplement the child's intake",
"     </li>",
"     <li>",
"      The use of supplemental multivitamins and minerals is prudent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Height and weight velocities, as well as changes in the body mass index, should be followed closely. If the child increases his or her dietary intake sufficiently, catch-up weight gain should be accomplished in a three- to six-month time frame.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Indications for referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial problems may require consultation with a behavioral psychologist or social worker. Families may need a referral to social services for financial assistance or to a clinical therapist for management of mental and behavioral problems. Occupational or speech therapy may be required for the treatment of oral motor or swallowing problems.",
"   </p>",
"   <p>",
"    Most preschool and school-age children with poor weight gain can be managed by their primary care provider once the factors contributing to inadequate dietary intake are identified. A registered dietitian may provide helpful guidance related to food and beverage selections, portion sizes, nutrient density of foods and beverages, and creative preparations of food sources.",
"   </p>",
"   <p>",
"    Referral to a specialist may be indicated for children in whom advanced diagnostic studies are required and for those in whom underlying medical conditions are identified. In cases where there is concern for an eating disorder, referral to a mental health provider or adolescent specialist may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/49/26386?source=see_link\">",
"       \"Patient information: Poor weight gain in babies and children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/18/8486?source=see_link\">",
"       \"Patient information: Poor weight gain in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor weight gain refers to abrupt weight loss following a period of normal growth along a well-established pattern, or weight gain that tracks along a growth channel either well below the fifth percentile of the growth curves (",
"      <a class=\"graphic graphic_figure graphicRef71721 graphicRef53325 \" href=\"mobipreview.htm?10/51/11064\">",
"       figure 1A-B",
"      </a>",
"      ) or a growth curve proportionate to, but lower than, the child's expected height trajectory (",
"      <a class=\"graphic graphic_figure graphicRef63399 graphicRef77249 \" href=\"mobipreview.htm?43/30/44519\">",
"       figure 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary cause of poor weight gain in preschool and school-age children and adolescents is inadequate dietary intake relative to metabolic and growth needs, which may be related to underlying medical, environmental, or social problems, alone or in combination. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic approach typically involves performing a complete history and physical examination to identify the major symptoms (",
"      <a class=\"graphic graphic_table graphicRef57170 \" href=\"mobipreview.htm?1/13/1244\">",
"       table 1",
"      </a>",
"      ) and etiologic categories (",
"      <a class=\"graphic graphic_table graphicRef68318 \" href=\"mobipreview.htm?38/13/39133\">",
"       table 2",
"      </a>",
"      ), screening for possible disease entities, initiating an empiric treatment regimen, and monitoring the clinical response. The pace of the evaluation is tailored to the severity of the problem. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important aspects of the physical examination are the growth measurements and the growth pattern. The pattern of growth helps to narrow the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Growth parameters'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nutritional counseling and dietary intervention are the first steps to therapy and should begin during the evaluation. If the child increases his or her dietary intake sufficiently, catch-up weight gain should be accomplished in a three- to six-month time frame. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/1\">",
"      Gahagan S. Failure to thrive: a consequence of undernutrition. Pediatr Rev 2006; 27:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Motil, KJ, Phillips, SM, Conkin, CA. Nutritional Assessment. In: Pediatric Gastrointestinal and Liver Disease. Pathophysiology, Diagnosis, Management (3rd ed), Wyllie, R, Hyams, JS, Kay, M (Eds), Elsevier, London 2006. p.1095.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/3\">",
"      Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/4\">",
"      Rudolph CD, Mazur LJ, Liptak GS, et al. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32 Suppl 2:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/5\">",
"      Acs G, Shulman R, Ng MW, Chussid S. The effect of dental rehabilitation on the body weight of children with early childhood caries. Pediatr Dent 1999; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/6\">",
"      Rogers B. Feeding method and health outcomes of children with cerebral palsy. J Pediatr 2004; 145:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/7\">",
"      Smith AM, Roux S, Naidoo NT, Venter DJ. Food choice of tactile defensive children. Nutrition 2005; 21:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/8\">",
"      Carruth BR, Ziegler PJ, Gordon A, Barr SI. Prevalence of picky eaters among infants and toddlers and their caregivers' decisions about offering a new food. J Am Diet Assoc 2004; 104:s57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/9\">",
"      Slupik RI. Managing adolescents with eating disorders. Int J Fertil Womens Med 1999; 44:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/10\">",
"      Valois S, Rising R, Duro D, et al. Carbohydrate malabsorption may increase daily energy requirements in infants. Nutrition 2003; 19:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/11\">",
"      Chelimsky G, Czinn SJ. Techniques for the evaluation of dyspepsia in children. J Clin Gastroenterol 2001; 33:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/12\">",
"      Kothare SV, Kaleyias J, Mostofi N, et al. Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006; 34:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/13\">",
"      Grosso S, Franzoni E, Iannetti P, et al. Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study. J Child Neurol 2005; 20:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/14\">",
"      Swenne I, Thurfjell B. Clinical onset and diagnosis of eating disorders in premenarcheal girls is preceded by inadequate weight gain and growth retardation. Acta Paediatr 2003; 92:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/15\">",
"      Mofidi S. Nutritional management of pediatric food hypersensitivity. Pediatrics 2003; 111:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/16\">",
"      Fortunato JE, Scheimann AO. Protein-energy malnutrition and feeding refusal secondary to food allergies. Clin Pediatr (Phila) 2008; 47:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/17\">",
"      Moilanen BC. Vegan diets in infants, children, and adolescents. Pediatr Rev 2004; 25:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/18\">",
"      Dunham L, Kollar LM. Vegetarian eating for children and adolescents. J Pediatr Health Care 2006; 20:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/19\">",
"      Block RW, Krebs NF, American Academy of Pediatrics Committee on Child Abuse and Neglect, American Academy of Pediatrics Committee on Nutrition. Failure to thrive as a manifestation of child neglect. Pediatrics 2005; 116:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/20\">",
"      van der Kuip M, Hoos MB, Forget PP, et al. Energy expenditure in infants with congenital heart disease, including a meta-analysis. Acta Paediatr 2003; 92:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/21\">",
"      Ackerman IL, Karn CA, Denne SC, et al. Total but not resting energy expenditure is increased in infants with ventricular septal defects. Pediatrics 1998; 102:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/22\">",
"      Bauer J, Maier K, Muehlbauer B, et al. Energy expenditure and plasma catecholamines in preterm infants with mild chronic lung disease. Early Hum Dev 2003; 72:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/23\">",
"      Lin YJ, Lee PC, Meng CC, Hwang B. Cor triatriatum with repeated episodes of syncope in an eighteen month-old girl: a rare cause of cardiogenic syncope. Int Heart J 2005; 46:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/24\">",
"      Mantzoros CS, Rosen HN, Greenspan SL, et al. Short-term hyperthyroidism has no effect on leptin levels in man. J Clin Endocrinol Metab 1997; 82:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/25\">",
"      Marcus CL, Carroll JL, Koerner CB, et al. Determinants of growth in children with the obstructive sleep apnea syndrome. J Pediatr 1994; 125:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/26\">",
"      Bonuck KA, Freeman K, Henderson J. Growth and growth biomarker changes after adenotonsillectomy: systematic review and meta-analysis. Arch Dis Child 2009; 94:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/27\">",
"      Pillai MG, Unnikrishnan AG, Nair V, et al. Diencephalic cachexia: a rare cause for failure to thrive. J Pediatr 2005; 147:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/28\">",
"      Fleischman A, Brue C, Poussaint TY, et al. Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics 2005; 115:e742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/29\">",
"      Vlachopapadopoulou E, Tracey KJ, Capella M, et al. Increased energy expenditure in a patient with diencephalic syndrome. J Pediatr 1993; 122:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/30\">",
"      Ahme ML, Ong KK, Thomson AH, Dunger DB. Reduced gains in fat and fat-free mass, and elevated leptin levels in children and adolescents with cystic fibrosis. Acta Paediatr 2004; 93:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/31\">",
"      Kumahara H, Tanaka H, Schutz Y. Daily physical activity assessment: what is the importance of upper limb movements vs whole body movements? Int J Obes Relat Metab Disord 2004; 28:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/32\">",
"      Spady DW, Payne PR, Picou D, Waterlow JC. Energy balance during recovery from malnutrition. Am J Clin Nutr 1976; 29:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/33\">",
"      Zangen T, Ciarla C, Zangen S, et al. Gastrointestinal motility and sensory abnormalities may contribute to food refusal in medically fragile toddlers. J Pediatr Gastroenterol Nutr 2003; 37:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/34\">",
"      Reilly S, Skuse D, Poblete X. Prevalence of feeding problems and oral motor dysfunction in children with cerebral palsy: a community survey. J Pediatr 1996; 129:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/35\">",
"      Levy Y, Levy A, Zangen T, et al. Diagnostic clues for identification of nonorganic vs organic causes of food refusal and poor feeding. J Pediatr Gastroenterol Nutr 2009; 48:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/36\">",
"      Hager ER, Quigg AM, Black MM, et al. Development and validity of a 2-item screen to identify families at risk for food insecurity. Pediatrics 2010; 126:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/37\">",
"      Kleinman RE, Murphy JM, Wieneke KM, et al. Use of a single-question screening tool to detect hunger in families attending a neighborhood health center. Ambul Pediatr 2007; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/38\">",
"      Hardin DS, Rice J, Ahn C, et al. Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition. J Pediatr 2005; 146:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38233/abstract/39\">",
"      Moy L, Levine J. Capsule endoscopy in the evaluation of patients with unexplained growth failure. J Pediatr Gastroenterol Nutr 2009; 48:647.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2877 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38233=[""].join("\n");
var outline_f37_21_38233=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Limited or inappropriate intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Increased needs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased losses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Energy cost of growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Present illness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Diet history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Past history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Social history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Review of systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Growth parameters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - General examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Initial tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Additional tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Advanced tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Dietary intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Indications for referral",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2877|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/61/14291\" title=\"figure 1A\">",
"      CDC weight for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/7/42098\" title=\"figure 1B\">",
"      CDC weight for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/1/44050\" title=\"figure 2A\">",
"      CDC stature for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/10/29858\" title=\"figure 2B\">",
"      CDC stature for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/45/28371\" title=\"figure 3\">",
"      Height measurement technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/23/38257\" title=\"figure 4A\">",
"      CDC BMI for age boys 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/2/40993\" title=\"figure 4B\">",
"      CDC BMI for age girls 2 to 20 years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/13/1244\" title=\"table 1\">",
"      FTT historical clues of organic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/13/39133\" title=\"table 2\">",
"      FTT examination",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/3/30769?source=related_link\" title=\"calculator 1\">",
"      Calculator: Mid-parental target height prediction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?35/14/36070?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Mass Index (BMI) percentiles for boys (2 to 20 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?34/60/35782?source=related_link\" title=\"calculator 3\">",
"      Calculator: Body Mass Index (BMI) percentiles for girls (2 to 20 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/60/28616?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13609?source=related_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/51/36664?source=related_link\">",
"      Cytomegalovirus infection and disease in newborns, infants, children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5321?source=related_link\">",
"      Diagnostic evaluation of food allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/11/23735?source=related_link\">",
"      Dietary energy requirements in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28631?source=related_link\">",
"      Dietary history and recommended dietary intake in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18441?source=related_link\">",
"      Dietary recommendations for toddlers, preschool, and school-age children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/22/17768?source=related_link\">",
"      Etiology and clinical manifestations of renal tubular acidosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/38/44649?source=related_link\">",
"      Evaluation of suspected obstructive sleep apnea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/2/6186?source=related_link\">",
"      Hepatitis C virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/55/22391?source=related_link\">",
"      Laboratory and radiologic evaluation of nutritional status in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/16/30985?source=related_link\">",
"      Management of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/40/42633?source=related_link\">",
"      Normal growth patterns in infants and prepubertal children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/58/16295?source=related_link\">",
"      Overview of hepatitis A virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/49/26386?source=related_link\">",
"      Patient information: Poor weight gain in babies and children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?8/18/8486?source=related_link\">",
"      Patient information: Poor weight gain in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38234="Treatment and prevention of pandemic H1N1 influenza ('swine influenza')";
var content_f37_21_38234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38234/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38234/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38234/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/21/38234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/21/38234/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/21/38234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In late March and early April 2009, an outbreak of H1N1 influenza A virus infection was detected in Mexico, with subsequent cases observed in many other countries, including the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In June 2009, the World Health Organization raised its pandemic alert level to the highest level, phase 6, indicating widespread community transmission on at least two continents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/3\">",
"     3",
"    </a>",
"    ]. The pandemic was declared to be over in August 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strategies used for the treatment and prevention of pandemic H1N1 influenza A virus infection will be reviewed here. The epidemiology, transmission, clinical manifestations, and diagnosis of pandemic H1N1 influenza A virus infection are discussed elsewhere. (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment and prevention of seasonal and avian (H5N1) influenza virus infections are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=see_link\">",
"     \"Treatment and prevention of avian influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412091\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section discusses the agents that were used during the 2009 to 2010 H1N1 influenza A pandemic. Recommendations for the treatment of seasonal influenza are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414876\">",
"    <span class=\"h2\">",
"     Antiviral agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412650\">",
"    <span class=\"h3\">",
"     Oseltamivir or zanamivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 2009 to 2010 H1N1 influenza A pandemic, the United States Centers for Disease Control and Prevention (CDC) released guidelines for the use of antivirals for patients with confirmed or suspected influenza virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5\">",
"     5",
"    </a>",
"    ]. For most patients with confirmed or suspected influenza infection requiring treatment, a neuraminidase inhibitor (orally inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ) was recommended. These medications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"     \"Treatment of seasonal influenza in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"     \"Pharmacology of antiviral drugs for influenza\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412464\">",
"    <span class=\"h3\">",
"     Intravenous zanamivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited quantities of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    were available for compassionate use from its manufacturer through an emergency investigational new drug application to the Food and Drug Administration (FDA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/6\">",
"     6",
"    </a>",
"    ]. Zanamivir was the preferred agent for patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant pandemic H1N1 influenza A infection. In those who were unable to use inhaled zanamivir (eg, critically-ill patients, patients with a history of bronchospasm), the intravenous formulation was considered appropriate.",
"   </p>",
"   <p>",
"    Favorable outcomes were reported in critically-ill children and adults who received intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. However, in a small retrospective study of critically-ill patients with pandemic H1N1 influenza A infection in the Netherlands who received IV zanamivir after having received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    , the late addition of zanamivir had limited effectiveness on viral load reduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/11\">",
"     11",
"    </a>",
"    ]. In 6 of 13 patients who had a sustained reduction of the viral load, the median time to starting zanamivir was 9 days (range 4 to 11 days) compared with 14 days (range 6 to 21 days) among the 7 patients who did not have a reduction in the viral load.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412471\">",
"    <span class=\"h3\">",
"     Peramivir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA issued emergency use authorization (EUA) for peramivir, an investigational neuraminidase inhibitor that is administered intravenously, for the treatment of certain hospitalized and critically-ill adults patients with suspected or confirmed pandemic H1N1 influenza A infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ]. The EUA for peramivir expired in June 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/14\">",
"     14",
"    </a>",
"    ]. Although peramivir has not been evaluated in large clinical trials, preliminary data suggest that it is as effective as oseltamivir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In an observational study, the 14-day, 28-day, and 56-day survival rates of 31 patients with severe pandemic H1N1 influenza A infection who received peramivir were 77, 67, and 59 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/17\">",
"     17",
"    </a>",
"    ]. Among adverse events reported to the United States Food and Drug Administration, rash was the only one that could be attributed to peramivir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was recommended that patients infected with a strain of influenza virus that was highly suspected or proven to be resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    not be treated with peramivir because of likely cross-resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Neuraminidase inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the CDC guidelines, prompt initiation of antiviral therapy was recommended for children, adolescents, or adults with suspected or confirmed influenza infection and any of the following features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Illness requiring hospitalization",
"     </li>",
"     <li>",
"      Progressive, severe, or complicated illness, regardless of previous health status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was also recommended that early treatment be considered in patients with suspected or confirmed influenza infection who were at high risk for complications including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children &lt;5 years of age, particularly those &lt;2 years of age",
"     </li>",
"     <li>",
"      Adults &ge;65 years of age",
"     </li>",
"     <li>",
"      Pregnant women and women up to two weeks postpartum (including those who have had pregnancy loss) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Individuals with certain medical conditions (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of seasonal influenza in adults\", section on 'Definition of high risk'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was recommended that for severely immunosuppressed patients (eg, those receiving treatment for malignancies, hematopoietic or solid organ transplant recipients) presenting with an acute respiratory illness, antiviral therapy be started as soon as possible.",
"   </p>",
"   <p>",
"    It was recommended that patients with morbid obesity (BMI &gt;40) and possibly those with obesity (BMI 30 to 39) with suspected or confirmed pandemic H1N1 influenza A virus infection be carefully evaluated for the presence of conditions that confer an increased risk of influenza complications. If any such conditions were present, treatment was recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=see_link\">",
"     \"Epidemiology of pandemic H1N1 influenza ('swine influenza')\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies of hospitalized patients with pandemic H1N1 influenza A have suggested that treatment with a neuraminidase inhibitor (most commonly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    ) reduced disease severity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Hospitalized patients",
"    </strong>",
"    &mdash; In a meta-analysis of 90 observational studies that evaluated the impact of neuraminidase inhibitor treatment in hospitalized patients, significant reductions in mortality were observed for early (&le;48 h after symptom onset) versus late treatment (odds ratio [OR] 0.38, 95% CI 0.27-0.53) and for early treatment versus no treatment (OR 0.35, 95% CI 0.18-0.71) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/22\">",
"     22",
"    </a>",
"    ]. Neuraminidase inhibitor treatment at any time versus no treatment was associated with an elevated risk of severe outcome (OR 1.76, 95% CI 1.22-2.54), but early treatment versus late treatment reduced the likelihood of severe outcome (OR 0.41, 95% CI 0.30-0.56). A non-significant trend towards mortality reduction was associated with neuraminidase inhibitor treatment at any time versus no treatment (OR 0.72, 95% CI, 0.51-1.01). A possible reason that treatment was associated with an elevated risk of severe outcome is that patients with mild disease were less likely to be treated, whereas those with severe disease were more likely to be treated.",
"    <br/>",
"    <br/>",
"    Individual studies showed the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 272 patients requiring hospitalization for pandemic H1N1 influenza A in the United States, the receipt of antiviral drugs within two days after the onset of illness was significantly associated with a positive outcome in a multivariable model [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 451 patients requiring hospitalization for pandemic H1N1 influenza A in the United States, patients with pneumonia were less likely to receive an antiviral agent within two days of illness onset than patients without pneumonia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 1291 patients in China with confirmed pandemic H1N1 influenza A infection, 95 percent of whom did not have a risk factor for complications,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      decreased the likelihood of developing pneumonia (odds ratio 0.12, 95% CI 0.08-0.18), even when started more than two days after symptom onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/25\">",
"       25",
"      </a>",
"      ]. Seventy-six percent of patients began oseltamivir on a median of the third day of symptoms. However, it is unclear how many patients had pneumonia at the time that treatment was initiated compared with following treatment initiation.",
"     </li>",
"     <li>",
"      In a study of 585 patients hospitalized for pandemic H1N1 influenza A infection in Spain, those who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      within 48 hours of presentation were less likely to develop pneumonia than those who did not (OR 0.29, 95% CI 0.19-0.46) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/26\">",
"       26",
"      </a>",
"      ]. In another analysis of 538 patients in the same cohort, longer time from onset of symptoms to oseltamivir administration (+1 day increase) was associated with a prolonged duration of fever (OR 1.10, 95% CI 1.02-1.19) and higher mortality (OR 1.20, 95% CI 1.06-1.35) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among hospitalized patients in Hong Kong with pandemic H1N1 influenza A or seasonal influenza, the receipt of antiviral therapy within 96 hours of onset of symptoms was associated with a reduced risk of death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/28\">",
"       28",
"      </a>",
"      ]. Conversely, if antiviral therapy was not received within 96 hours, patients with pandemic H1N1 influenza A had a higher risk of death than patients with seasonal influenza (OR 6.85, 95% CI 1.64-28.65).",
"     </li>",
"     <li>",
"      Among hospitalized patients with pandemic H1N1 influenza A in New York City, the 28 patients who died were less likely to have received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      within two days of hospitalization than the 98 patients who survived (61 versus 96 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Critically-ill patients",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1859 critically-ill patients with pandemic H1N1 influenza A infection in California, neuraminidase inhibitor treatment (mostly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      ) was associated with increased survival compared with no treatment (75 percent versus 58 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/30\">",
"       30",
"      </a>",
"      ]. The median time from symptom onset to starting neuraminidase inhibitor treatment was four days. Treatment initiated within five days after symptom onset was associated with increased survival compared with those who did not receive antiviral therapy. There was a trend towards increased survival among those treated earliest.",
"     </li>",
"     <li>",
"      Among 657 patients requiring intensive care in Spain, those receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      treatment within 48 hours of symptom onset had lower intensive care unit mortality than those who began treatment later [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 58 critically-ill patients in Mexico with confirmed, probable, or suspected pandemic H1N1 influenza A infection, after excluding patients who died within 72 hours of presentation who may have had less opportunity to be exposed to antiviral therapy, survivors were more likely than nonsurvivors to have received treatment with a neuraminidase inhibitor (OR 7.4, 95% CI 1.8-31) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Children",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among hospitalized children in Spain with pandemic H1N1 influenza A, those in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      was delayed for &gt;72 hours following onset of symptoms were more likely to require intensive care unit admission than those who received earlier treatment (OR 3.7, 95% CI 1.1-11.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Pregnant women",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among pregnant women with pandemic H1N1 influenza A in the United States, those who began antiviral therapy more than four days after symptom onset were more likely to be admitted to an intensive care unit than those who began therapy within two days (57 versus 9 percent; relative risk 6.0, 95% CI 3.5-10.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among severely ill pregnant women with pandemic H1N1 influenza A infection in the United States, treatment was started later in those who died compared with those who survived; only 7 percent of women who died received a neuraminidase inhibitor within two days of illness onset compared with 41 percent of women who survived [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/35\">",
"       35",
"      </a>",
"      ]. Women who died were less likely to have received a neuraminidase inhibitor than women who survived (86 verus 95 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Immunocompromised hosts",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 237 pediatric and adult solid organ transplant recipients with pandemic H1N1 influenza A, there was a lower rate of intensive care unit admission among those who received antiviral therapy within 48 hours of symptom onset compared with those who received antiviral therapy later (8 versus 22 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/36\">",
"       36",
"      </a>",
"      ]. Nearly all of the patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a retrospective study that included 304 hematopoietic cell transplant recipients with influenza infection, 161 (53 percent) of whom had pandemic H1N1 influenza A infection, antiviral therapy for upper respiratory tract disease (URD) within 48 hours of diagnosis was associated with a reduced risk of lower respiratory tract disease (LRD; adjusted odds ratio [aOR] 0.04, 95% CI 0.0-0.2), hypoxemia (aOR 0.14, 95% CI 0.0-0.4), as well as overall death at six weeks and six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/37\">",
"       37",
"      </a>",
"      ]. Antiviral therapy initiated beyond 48 hours after URD diagnosis was also associated with a reduced risk of LRD (aOR 0.14, 95% CI 0.0-0.7). Early antiviral therapy for URD showed only a trend for reduced risk of influenza-associated death compared with no antiviral therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532740\">",
"    <span class=\"h2\">",
"     Antibacterial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary bacterial pneumonia was detected in some patients with pneumonia caused by pandemic H1N1 influenza A, particularly in those with severe disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It was recommended that patients with pandemic H1N1 influenza A who developed pneumonia be treated empirically for community-acquired pneumonia (CAP) given the risk of secondary bacterial pneumonia with organisms such as Streptococcus pneumoniae and Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5,38,39\">",
"     5,38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25354?source=see_link&amp;anchor=H12#H12\">",
"     \"Inpatient treatment of pneumonia in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors had different recommendations for when and how to initiate antibacterial therapy for secondary pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H532747\">",
"    <span class=\"h2\">",
"     Other treatment modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several adjunctive approaches have been evaluated for the treatment of pandemic H1N1 influenza A infection, including extracorporeal membrane oxygenation, N-acetyl cysteine, and glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2914387\">",
"    <span class=\"h3\">",
"     Extracorporeal membrane oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal membrane oxygenation (ECMO) was used in some patients with acute respiratory distress syndrome resulting from severe pandemic H1N1 influenza A infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. One observational study suggested that there was a mortality benefit in patients who were referred to a specialized center to receive ECMO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/41\">",
"     41",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=see_link&amp;anchor=H3#H3\">",
"     \"Extracorporeal membrane oxygenation (ECMO) in adults\", section on 'Acute respiratory failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2914394\">",
"    <span class=\"h3\">",
"     N-acetyl cysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-acetyl cysteine, an antioxidant, was reported to attenuate the cytokine storm associated with severe influenza infection and was used as an adjunctive agent in one patient with severe pandemic H1N1 influenza A infection who subsequently experienced clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/43\">",
"     43",
"    </a>",
"    ]. Further studies will be needed to determine whether N-acetyl cysteine improves outcomes in patients with influenza infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533005\">",
"    <span class=\"h3\">",
"     Effect of glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are often used in the setting of septic shock based on results from randomized trials (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16281?source=see_link\">",
"     \"Corticosteroid therapy in septic shock\"",
"    </a>",
"    ). Their use in patients with influenza infections has only been evaluated in retrospective studies, with conflicting results. In a retrospective study that evaluated clinical outcomes in hematopoietic cell transplant recipients with pandemic H1N1 influenza infection, those who received high-dose glucocorticoids (&ge;1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ) at the time of influenza diagnosis had a reduced risk of requiring mechanical ventilation (adjusted odds ratio 0.07, 95% CI 0.0-0.7) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, in a retrospective cohort study of noncritically-ill hospitalized patients with pandemic H1N1 influenza A infection in China, where glucocorticoids are sometimes used as antipyretics, the use of glucocorticoids was associated with the subsequent development of critical illness even after adjustment for the presence of underlying diseases or risk factors (hazard ratio 2.9, 95% CI 1.3-6.2); critical illness was defined as the presence of any of the following features: death, respiratory failure, septic shock, failure or insufficiency of &ge;2 nonpulmonary organs, mechanical ventilation, or intensive care unit admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study is necessary to determine whether glucocorticoids are harmful or beneficial in patients with influenza infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H412957\">",
"    <span class=\"h1\">",
"     ANTIVIRAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When antiviral prophylaxis was indicated, either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    was recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5183765\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC stated that postexposure antiviral prophylaxis could be considered for adults and children who had close contact with a confirmed or suspected case",
"    <strong>",
"     AND",
"    </strong>",
"    also fell into one of the following categories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5,45\">",
"     5,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults who are at high risk for complications of influenza (eg, individuals with certain chronic medical conditions or who are greater than 65 years of age).",
"     </li>",
"     <li>",
"      Pregnant women and women who are up to two weeks postpartum (including following pregnancy loss) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children who are &lt;5 years of age or who are at high risk of complications of influenza.",
"     </li>",
"     <li>",
"      Healthcare workers and emergency medical personnel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413372\">",
"    <span class=\"h2\">",
"     Prophylaxis in closed settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;No outbreaks of pandemic H1N1 influenza A virus were identified in nursing homes, although clusters were identified in long-term care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5,46\">",
"     5,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For outbreaks in nursing homes or long-term care facilities, it was recommended that ill patients be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    , and prophylaxis with oseltamivir or zanamivir be initiated as soon as possible to all non-ill residents. The recommended duration of prophylaxis was a minimum of two weeks AND until approximately seven days after illness onset of the last patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"     \"Prevention of seasonal influenza in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiviral prophylaxis could also be considered during outbreaks in other closed or semiclosed settings (eg, correctional facilities), where large numbers of individuals at increased risk for influenza complications are housed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    ring prophylaxis was used during four outbreaks of pandemic H1N1 influenza A in military units in Singapore; ring prophylaxis involved the use of oseltamivir 75 mg once daily to members of the same military unit where contact opportunities were substantial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/47\">",
"     47",
"    </a>",
"    ]. Larger prophylaxis rings were used if cases were present in multiple units, and other infection control measures were also implemented. Before oseltamivir prophylaxis and the other measures were instituted, the proportion of individuals with infection was 6.4 percent, and fell to 0.6 percent following the interventions. These results suggest that the use of early and aggressive infection control measures, including ring prophylaxis, can reduce transmission of influenza in closed and semiclosed settings.",
"   </p>",
"   <p>",
"    In a university setting where more than a 1000 visits for respiratory illness occurred in a one week period in the spring of 2009, more than 500 courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    were distributed; the outbreak subsequently subsided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     DRUG RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral drug resistance among pandemic H1N1 influenza A virus strains is presented below. Resistance among seasonal influenza viruses is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neuraminidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of strains of pandemic H1N1 influenza A virus circulating in 2009 were susceptible in vitro to the neuraminidase inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Greater than 99 percent of influenza isolates circulating in the United States during the 2009 to 2010 pandemic were the pandemic strain of H1N1 influenza A, the vast majority of which were susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/49\">",
"     49",
"    </a>",
"    ]. The low rate of oseltamivir resistance among pandemic H1N1 influenza A strains contrasted with the extremely high rate among seasonal H1N1 influenza A strains. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link&amp;anchor=H527111#H527111\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\", section on 'Oseltamivir resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12594437\">",
"    <span class=\"h3\">",
"     H274Y mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small minority of isolates of pandemic H1N1 influenza A virus with resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    were detected from patients in several countries, including Japan, the United States, China, Hong Kong, Singapore, Vietnam, Denmark, and Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/50-64\">",
"     50-64",
"    </a>",
"    ]. Among 37 cases in the United States, 76 percent occurred in severely immunocompromised patients and 89 percent occurred in patients who had received oseltamivir; thus, both features appear to be risk factors for the development of oseltamivir resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/60\">",
"     60",
"    </a>",
"    ]. However, in a community cluster of oseltamivir-resistant pandemic H1N1 influenza A infection in Vietnam, none of the individuals had received oseltamivir prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/57\">",
"     57",
"    </a>",
"    ]. The neuraminidase mutation, H274Y, which caused widespread oseltamivir resistance among seasonal H1N1 influenza A isolates beginning in 2007, was also detected in isolates from patients with oseltamivir-resistant pandemic H1N1 influenza A infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/50,56\">",
"     50,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=see_link&amp;anchor=H527111#H527111\">",
"     \"Antiviral drug resistance among seasonal influenza viruses\", section on 'Oseltamivir resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two nosocomial clusters of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant pandemic H1N1 influenza A infection were identified in Wales and the United States; both clusters involved hematology-oncology wards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. In one study, 8 of 10 case patients had oseltamivir-resistant virus, and 4 of 8 were infected by direct transmission of resistant virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/65\">",
"     65",
"    </a>",
"    ]. Most of the patients whose clinical courses were reported recovered without complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/51,56\">",
"     51,56",
"    </a>",
"    ], although some immunocompromised patients died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. In a case-control study, patients infected with an oseltamivir-resistant virus were more likely to be immunocompromised and to develop respiratory complications than patients infected with an oseltamivir-susceptible virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid development of resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    was described in hematopoietic cell transplant (HCT) recipients and patients with malignancies during treatment for pandemic H1N1 influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/58,69\">",
"     58,69",
"    </a>",
"    ]. All of these patients&rsquo; viral isolates remained susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    . One HCT recipient developed resistance not only to oseltamivir, but also to peramivir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sustained community transmission of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -resistant pandemic H1N1 influenza A was identified in 29 individuals in New South Wales, Australia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Hemagglutinin and neuraminidase sequence analysis indicated that the resistant strains were closely related, suggesting the spread of a single variant. Only one patient had received oseltamivir prior to collection of a respiratory specimen for resistance testing.",
"   </p>",
"   <p>",
"    Using deep sequencing, the virus population was surveyed from a 15-year-old boy with T cell leukemia and pandemic H1N1 influenza A infection who was receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/70\">",
"     70",
"    </a>",
"    ]. The patient was found to be harboring three genetic variants from phylogenetically distinct viral clades, strongly suggestive of a mixed infection. In response to treatment, one of the variants developed the neuraminidase mutation, H274Y, which confers resistance to oseltamivir.",
"   </p>",
"   <p>",
"    In another study, ultra-deep sequencing was used to evaluate pandemic H1N1 influenza A virus populations from nasopharyngeal specimens from two infected individuals from a single household and from an infected immunocompromised child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/71\">",
"     71",
"    </a>",
"    ]. The H274Y mutation was present as a minor variant in infected individuals prior to the onset of therapy. In addition, isolates possessing the H274Y mutation were transmitted together with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    -susceptible strains. The H275Y mutation could not be detected by conventional reverse-transcriptase polymerase chain reaction assays or by Sanger sequencing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12594466\">",
"    <span class=\"h3\">",
"     S247N mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since December 2010, a variant of the pandemic H1N1 influenza A virus possessing a mutation at residue 247 of the neuraminidase gene (S247N) has been detected in 22 samples from the Asia Pacific region collected for the World Health Organization&rsquo;s Global Influenza Surveillance Network [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/72\">",
"     72",
"    </a>",
"    ]. This mutation confers some",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"     zanamivir",
"    </a>",
"    resistance; the mean half maximal inhibitory concentration (IC",
"    <sub>",
"     50",
"    </sub>",
"    ) for oseltamivir was increased sixfold and for zanamivir was increased threefold. During the first three months of 2011, 9 of 28 samples (32 percent) from the Darwin region of northern Australia and 10 of 80 samples (12.5 percent) from Singapore contained the S247N mutation; the majority of isolates have been detected in two clusters in these regions. This variant has also been detected rarely since 2009 in seasonal H1N1 influenza and avian H5N1 influenza isolates in other parts of the world. When combined with the H275Y mutation, as detected in an immunocompromised patient treated with oseltamivir, the dual",
"    <span class=\"nowrap\">",
"     S247N/H275Y",
"    </span>",
"    mutant had a 7000-fold increase in IC",
"    <sub>",
"     50",
"    </sub>",
"    to oseltamivir and a fivefold increase in IC",
"    <sub>",
"     50",
"    </sub>",
"    to zanamivir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12594473\">",
"    <span class=\"h3\">",
"     Multidrug resistance mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare reports emerged of multidrug resistance mutations in patients treated for pandemic H1N1 influenza, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 14-year-old patient with systemic lupus erythematosus, systemic vasculitis, and chronic pancreatitis who was receiving immunosuppressive medications and who died from complications of pandemic H1N1 influenza A infection was infected with a strain that had two neuraminidase mutations, H274Y and I223R; the I223R mutation involves an isoleucine to arginine amino acid substitution at residue 223 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/73\">",
"       73",
"      </a>",
"      ]. Following treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      , the patient&rsquo;s influenza virus isolates developed high-grade resistance to oseltamivir, and lesser degrees of resistance to peramivir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      A 5-year-old boy with acute lymphoblastic leukemia received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      for pandemic H1N1 influenza A infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/74\">",
"       74",
"      </a>",
"      ]. He responded to therapy, but repeat testing of a respiratory sample following hematopoietic stem cell transplantation was positive for pandemic H1N1 influenza A that possessed the H274Y mutation. He was started on intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      , which resulted in clinical improvement. However, several weeks later he had worsening lower respiratory tract symptoms, leading to acute respiratory distress syndrome and death. Testing of the virus that was obtained while he was critically ill revealed the presence of an I223R mutation, conferring reduced susceptibility to oseltamivir (45-fold elevated 50 percent inhibitory concentration [IC",
"      <sub>",
"       50",
"      </sub>",
"      ]), zanamivir (10-fold elevated IC",
"      <sub>",
"       50",
"      </sub>",
"      ), and peramivir (7-fold elevated IC",
"      <sub>",
"       50",
"      </sub>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"     Oseltamivir",
"    </a>",
"    -resistant pandemic H1N1 influenza A isolates possessing the H274Y neuraminidase mutation collected from immunocompromised patients retained replicative fitness, transmissibility, and virulence in a ferret model of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Adamantanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;All strains of pandemic H1N1 influenza A tested were resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"     rimantadine",
"    </a>",
"    ; thus these medications were not recommended for treating suspected H1N1 influenza infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/51,76-78\">",
"     51,76-78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H413651\">",
"    <span class=\"h1\">",
"     VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the 2009 to 2010 influenza season, it was necessary for individuals to be vaccinated against pandemic H1N1 influenza A using a monovalent vaccine, since the trivalent (seasonal) influenza vaccine did not contain antigens from this strain. Starting with the 2010 influenza season in the southern hemisphere and the 2010 to 2011 season in the northern hemisphere, the trivalent influenza vaccine included antigen from the 2009 pandemic H1N1 influenza A virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link&amp;anchor=H3#H3\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Antigenic composition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The CDC recommended that H1N1 influenza vaccine be given to ALL persons six months of age and older. When the vaccine supply was limited in the fall of 2009, health officials created a priority list for administration of H1N1 influenza vaccine that included pregnant women, household contacts and caregivers of children younger than 6 months of age, healthcare and emergency medical services personnel, individuals from 6 months through 24 years of age, and individuals from 25 through 64 years of age with health conditions associated with increased risk of influenza complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414235\">",
"    <span class=\"h2\">",
"     Cross-protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies suggested that vaccination against pandemic H1N1 influenza A would not provide protection against seasonal strains of influenza, and that vaccination against seasonal influenza would not provide protection against pandemic H1N1 influenza A infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/48,82-85\">",
"     48,82-85",
"    </a>",
"    ]. However, one case-control study in Mexico City that included 60 patients with laboratory-confirmed pandemic H1N1 influenza A infection and 180 controls suggested that individuals who had received the 2008 to 2009 seasonal influenza vaccine were less likely to develop pandemic H1N1 influenza A infection (adjusted odds ratio 0.27, 95% CI 0.11 to 0.66) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/86\">",
"     86",
"    </a>",
"    ]. In another study, vaccination with an inactivated seasonal influenza vaccine resulted in elevated antibodies against the pandemic H1N1 neuraminidase in an age-dependent manner, with significant responses among those &gt;60 years and the highest responses among those &ge;85 years, suggesting that the seasonal influenza vaccine may boost immunity to influenza viruses related to pandemic H1N1 influenza A among elderly individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/87\">",
"     87",
"    </a>",
"    ]. A study of the 2009 pandemic H1N1 influenza A virus vaccine indicated that it could also boost pre-existing neutralizing antibodies against some, but not all, influenza virus strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher proportion of individuals who received the 1976 swine influenza vaccine had neutralizing antibody responses &ge;160 against 2009 pandemic H1N1 influenza A compared with individuals who did not receive this vaccine (17 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/89\">",
"     89",
"    </a>",
"    ]. In addition, passive transfer of human serum from individuals who had been vaccinated with the 1976 swine influenza vaccine protected mice against a lethal challenge of the 2009 pandemic H1N1 influenza A virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414242\">",
"    <span class=\"h2\">",
"     Possible increased risk following seasonal influenza vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;During an investigation of a school-based outbreak of pandemic H1N1 influenza A in British Columbia, Canada, it was noted that individuals who had previously received the trivalent inactivated seasonal influenza vaccine were more likely to develop pandemic H1N1 influenza A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/91\">",
"     91",
"    </a>",
"    ]. Four observational studies were subsequently performed that included 1226 laboratory-confirmed cases of pandemic H1N1 influenza A and 1505 controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/92\">",
"     92",
"    </a>",
"    ]. Prior vaccination with the 2008 to 2009 trivalent inactivated seasonal influenza vaccine was associated with an increased risk of medically attended pandemic H1N1 influenza during the spring and summer of 2009, with estimated risk ratios or odds ratios of 1.4 to 2.6. A study of children in Japan showed similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although several hypotheses for this finding have been proposed, none has been proven, and the observational design makes confounding a possible explanation. Several other studies have not shown such an association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/48,84-86,94\">",
"     48,84-86,94",
"    </a>",
"    ]. In one study, children who had recent seasonal influenza infection had a lower risk of laboratory-confirmed 2009 to 2010 pandemic influenza A infection (adjusted odds ratio 0.35, 95% CI 0.14-0.87) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/85\">",
"     85",
"    </a>",
"    ]. However, receipt of the 2008 seasonal trivalent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/61/985?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    did not affect the risk of pandemic influenza A infection. It is possible that natural seasonal influenza infection provided cross-protection against 2009 to 2010 pandemic influenza A, and that individuals who were vaccinated against seasonal influenza virus in 2008 were less likely to benefit from the protection provided by natural infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414256\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414264\">",
"    <span class=\"h3\">",
"     Laboratory assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the immunogenicity of the H1N1 influenza vaccine evaluate the proportion of persons who achieve certain immunologic endpoints, such as a particular threshold of antibody production against vaccine antigens or a four-fold (or greater) increase in geometric mean titer (GMT) antibodies.",
"   </p>",
"   <p>",
"    Antibody levels are measured with the hemagglutination-inhibition assay or the microneutralization assay; protection against infection is inferred by the height of the antibody levels, although it is not possible to determine the specific threshold needed against individual virus strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/96\">",
"     96",
"    </a>",
"    ]. Most studies have correlated antibody titers of 1:40 or more on either assay with evidence of vaccine immunogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/97,98\">",
"     97,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414271\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of nonadjuvanted vaccine (with hemagglutinin antigen doses ranging from 7.5 mcg to 30 mcg) demonstrated immunogenicity in 93 to 100 percent of healthy adults with receipt of a single dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. Modest decrements of response were noted among persons over 60 years of age in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/100\">",
"     100",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/98\">",
"     98",
"    </a>",
"    ], studies. In one trial, antibody responses in very elderly adults (&ge;75 years) were superior to those in younger elderly adults (65 to 74 years); 97 percent of very elderly adults achieved hemagglutinin-inhibition titers &gt;1:40 compared with 90 percent of younger elderly adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/99\">",
"     99",
"    </a>",
"    ]. In addition, postvaccination serum samples from elderly adults (aged 66 to 83 years) had higher avidity and slower antibody dissociation rates than those from adults &le;65 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial demonstrated comparable immunogenicity between alum-adjuvanted and nonadjuvanted vaccines among 1210 adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/100\">",
"     100",
"    </a>",
"    ]. In contrast, another randomized clinical trial demonstrated improved immunogenicity of MF59-adjuvanted vaccine compared with nonadjuvanted vaccine among 176 healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/102\">",
"     102",
"    </a>",
"    ]. Another trial showed that a single dose of 15 mcg of nonadjuvanted split virion vaccine was more immunogenic than 15 mcg of alum-adjuvanted split virion vaccine or 10 mcg of alum-adjuvanted whole virion vaccine in healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/103\">",
"     103",
"    </a>",
"    ]. This trial also showed that seroprotective immune responses were detectable as early as 14 days following vaccination; 97 percent of individuals who received the nonadjuvanted split virion vaccine had hemagglutinin-inhibition titers &ge;1:40 at this time point. In trials that included adults and elderly adults, two doses of an oil-in-water (AS03",
"    <sub>",
"     A",
"    </sub>",
"    )-adjuvanted vaccine was more immunogenic than two doses of a nonadjuvanted whole virion vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an open-label study, a single 3.75 mcg dose of vaccine adjuvanted with AS03",
"    <sub>",
"     A",
"    </sub>",
"    resulted in adequate immunogenicity in 98 percent of individuals between 18 and 60 years of age and 87 percent of individuals over 60 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/106\">",
"     106",
"    </a>",
"    ]. In a separate trial of the same vaccine, immune responses remained robust six months after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414278\">",
"    <span class=\"h3\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized trial that included 120 pregnant women, a single dose of a nonadjuvanted pandemic H1N1 influenza vaccine containing either 25 mcg or 49 mcg of the hemagglutinin antigen resulted in seroprotection in 93 and 97 percent of women, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/108\">",
"     108",
"    </a>",
"    ]. Other studies have shown similar results in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. Seroprotective titers were found in 87 and 89 percent of cord blood samples from women who received the 25 mcg or the 49 mcg dose, respectively, suggesting that efficient transplacental transfer of antibodies occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, pregnant women who had received the seasonal influenza vaccine prior to receiving the pandemic H1N1 influenza A vaccine, particularly those who received it &le;19 days earlier, had a lower antibody response after the first dose of the pandemic H1N1 influenza A vaccine than those who had not received the seasonal influenza vaccine (adjusted odds ratio 0.15, 95% CI 0.03-0.80) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414285\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials were performed to determine the immunogenicity of various nonadjuvanted H1N1 influenza vaccines in children; there were conflicting results as to whether a one- or two-dose schedule is needed in children less than nine years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/100,111-113\">",
"     100,111-113",
"    </a>",
"    ]. However, varying outcomes of vaccine immunogenicity could be secondary to circulating virus, which may differ based on geographic locale. Without a placebo group, it is often difficult to determine whether subclinical infection may have boosted the immune response elicited by vaccine in some trials and not in others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a double-blind, randomized controlled trial that did include a placebo arm, seroconversion rates after a single dose of nonadjuvanted split-virion vaccine (7.5 mcg hemagglutinin per dose) were 77 percent among children 3 to &lt;12 years of age compared with 10 percent among those in the placebo arm; a second dose of vaccine boosted seroconversion rates to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/114\">",
"     114",
"    </a>",
"    ]. In a case-control study, a single dose of nonadjuvanted vaccine was 82 percent effective in preventing hospitalization in children between three and nine years of age, but was ineffective in children between 7 and 35 months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/115\">",
"     115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study in Costa Rica supported the need for adjuvanted vaccine for children less than nine years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/116\">",
"     116",
"    </a>",
"    ]. In another study that compared two doses of an oil-in-water (AS03",
"    <sub>",
"     A",
"    </sub>",
"    )-adjuvanted pandemic H1N1 influenza vaccine to two doses of a nonadjuvanted whole virion pandemic H1N1 influenza vaccine in children six months to 12 years of age, seroconversion rates in children under 3 years of age were higher after adjuvanted vaccine than nonadjuvanted vaccine (98 versus 80 percent); in contrast, seroconversion rates were high following either vaccine in those over three years (99 versus 96 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/117\">",
"     117",
"    </a>",
"    ]. Adjuvanted vaccine was more reactogenic than nonadjuvanted vaccine, especially after the second dose. Persistence of pandemic H1N1 antibodies (defined as a microneutralization titer &ge;1:40) one year after initial vaccination was higher in those that received adjuvanted vaccine than in those who received non-adjuvanted vaccine (100 versus 32 percent in those immunized at &lt;3 years of age; 97 versus 66 percent in those who were 3 to 12 years of age at immunization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414769\">",
"    <span class=\"h3\">",
"     HIV-infected individuals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the immunogenicity of nonadjuvanted pandemic H1N1 influenza A vaccines among HIV-infected patients have shown low rates of seroconversion, whereas adjuvanted vaccines have generally shown higher rates of seroconversion. This is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations in HIV-infected patients\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624651914\">",
"    <span class=\"h3\">",
"     Solid organ transplant recipients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study in which solid organ transplant (SOT) recipients who received two doses of an adjuvanted vaccine were compared with healthy individuals who received only one dose, 52 percent of SOT recipients seroconverted (as measured by hemagglutinin-inhibition) at both day 21 and day 49, compared with 67 percent of healthy individuals at day 21 and 77 percent at day 49 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74638892\">",
"    <span class=\"h3\">",
"     Patients with hematologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study that included 62 patients with hematologic malignancies who received an oil-in-water adjuvanted monovalent pandemic H1N1 influenza A vaccine, only 13 patients (21 percent) developed seroprotective titers versus none of 41 unvaccinated controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/120\">",
"     120",
"    </a>",
"    ]. By comparison, in another study, 98 percent of healthy individuals developed seroprotective titers to the same vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anti-CD20 monoclonal antibody,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , has become a standard part of the treatment of CD20-positive B cell lymphomas. Since this agent depletes normal B cells, there is concern that it will attenuate the response to vaccines. In a study of lymphoma patients who had received a rituximab-containing treatment regimen within the previous six months, none of 67 patients developed seroprotective titers following administration of an oil-in-water adjuvanted monovalent inactivated pandemic H1N1 influenza A vaccine; in contrast, 42 of 51 healthy controls (82 percent) developed seroprotective titers following vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11840296\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of different formulations of monovalent pandemic H1N1 influenza A vaccine has varied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/123-126\">",
"     123-126",
"    </a>",
"    ], as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following a large campaign in China to vaccinate individuals against pandemic H1N1 influenza A using a single dose of a nonadjuvanted monovalent split-virion vaccine of 15 mcg of hemagglutinin antigen, the estimated vaccine effectiveness among children between 4 and 17 years of age was 87.3 percent (95% CI 75.4-93.4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational study of high-risk target groups in England, the effectiveness of a single dose of an adjuvanted oil-in-water pandemic H1N1 influenza A vaccine was estimated to be 62 percent (95% CI 33 to 78 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/124\">",
"       124",
"      </a>",
"      ]. Effectiveness varied by age, being 77 percent in children &lt;10 years, 100 percent in 10 to 24 year-olds, 22 percent in 25 to 49 year-olds, and 41 percent in individuals &ge;50 years.",
"     </li>",
"     <li>",
"      In a population-based cohort study in Sweden, the effectiveness of a single dose of an AS03-adjuvanted pandemic H1N1 influenza A vaccine was estimated to be 87 to 95 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/125\">",
"       125",
"      </a>",
"      ]. Individuals with vaccine failure were more likely to be immunocompromised than age-matched controls who did not experience vaccine failure (hazard ratio 4.89, 95% CI 2.19-10.89).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414292\">",
"    <span class=\"h2\">",
"     Coadministration of pandemic H1N1 and seasonal influenza vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggested that immunogenicity is retained if pandemic and seasonal influenza vaccines are coadministered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/127,128\">",
"     127,128",
"    </a>",
"    ]. One prospective trial randomly assigned 355 adult patients to either pandemic vaccine (a monovalent whole virus vaccine with 6 mcg of hemagglutinin and aluminum phosphate adjuvant) or pandemic vaccine coadministered with seasonal vaccine to assess the immunogenicity and safety of giving two vaccines at once [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/127\">",
"     127",
"    </a>",
"    ]. Comparable seroconversion rates were achieved among patients in both arms and safety outcomes were also similar; local pain at the injection site was the most commonly reported adverse event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415304\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;In assessing vaccine safety, it is important to know the background rates of disease in the population in order to separate out legitimate safety concerns from events that are temporally associated, but not caused by vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/129\">",
"     129",
"    </a>",
"    ]. In addition, intensive safety monitoring is critical for detecting adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/130\">",
"     130",
"    </a>",
"    ]. The pandemic H1N1 influenza vaccine appears to have been safe and well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415319\">",
"    <span class=\"h3\">",
"     Vaccine Adverse Event Report System (VAERS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC has reported vaccine safety results for the pandemic H1N1 influenza A vaccines for the first two months of the vaccination campaign (October 1 to November 24, 2009) based upon 3783 reports from the United States",
"    <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"     Vaccine Adverse Event Report System (VAERS)",
"    </a>",
"    and 438,376 individuals vaccinated in managed care organizations reported through the Vaccine Safety Datalink (VSD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/131\">",
"     131",
"    </a>",
"    ]. VAERS data showed 82 adverse events per million pandemic H1N1 influenza vaccine doses distributed compared with 47 per million for the seasonal influenza vaccine. However, no substantial differences in the proportion or types of serious adverse events were observed between the pandemic H1N1 and seasonal influenza vaccines.",
"   </p>",
"   <p>",
"    There have also been 11 reports of anaphylaxis and eight reports of possible anaphylaxis; of these 19 reports, 13 met criteria for anaphylaxis, five had a diagnosis of anaphylaxis on medical record review, and one has not been confirmed.",
"   </p>",
"   <p>",
"    No increase in adverse events was observed relative to comparator groups in the VSD database.",
"   </p>",
"   <p>",
"    In a subsequent report about the VAERS database, the rate of serious events reported for the pandemic H1N1 influenza A vaccine was 8.8 per million doses, compared with 4.1 per million doses reported for the seasonal influenza vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H640151200\">",
"    <span class=\"h3\">",
"     Postmarketing surveillance in China",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a postmarketing surveillance study in China, which involved passive reporting, nonadjuvanted split virion pandemic H1N1 influenza A vaccines were well-tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/133\">",
"     133",
"    </a>",
"    ]. Approximately 89.6 million doses of vaccine were administered from late September 2009 until late March 2010, and 8067 vaccinees reported having an adverse reaction (90 events per million doses). The age-specific rates of adverse events ranged from 31.4 per million doses among individuals &ge;60 years of age to 130.6 per million doses among individuals &le;9 years of age. Of the 8067 adverse events, 6552 (81.2 percent) were verified to be vaccine reactions (73.1 events per million doses); 1083 of the 8067 events (13.4 percent; 12.1 events per million doses) were considered more serious than the typical minor events, most of which were allergic reactions. Eleven cases of Guillain-Barr&eacute; syndrome were reported (0.1 cases per million doses), which is lower than the background rate in China.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415326\">",
"    <span class=\"h3\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1976, approximately 45 million people in the United States were immunized against an influenza virus of swine origin, but the program was discontinued prematurely, in part due to an increased incidence of Guillain-Barr&eacute; syndrome among vaccinees and because of the low number of confirmed cases of influenza virus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/134\">",
"     134",
"    </a>",
"    ]. Although the syndrome was rare, the attributable risk of Guillain-Barr&eacute; syndrome was estimated to be 1 per 100,000 within eight weeks following vaccination, which represented a seven-fold increase in risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Baseline frequencies of Guillain-Barr&eacute; syndrome were established through epidemiologic surveys in various parts of the globe in order to assess any association of this neurologic complication with infection (including influenza itself) or any preventive measures (eg, immunization) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/135\">",
"     135",
"    </a>",
"    ]. Various studies have been performed to assess the risk of Guillain-Barr&eacute; syndrome following vaccination with a pandemic H1N1 influenza vaccine, most of which have not demonstrated an elevated risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitoring through the",
"      <a class=\"external\" href=\"file://vaers.hhs.gov/index\">",
"       VAERS",
"      </a>",
"      showed no increase in incidence of cases following the introduction of the H1N1 influenza vaccine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/131,132\">",
"       131,132",
"      </a>",
"      ]. In fact, the reporting rate of Guillain-Barr&eacute; syndrome was less than the expected background rate in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The CDC&rsquo;s Emerging Infections Program, an active surveillance program, found a very small increase in cases of Guillain-Barr&eacute; syndrome (0.8 excess cases per 1 million vaccinations) in patients who received the pandemic H1N1 influenza A vaccine compared with patients who were not vaccinated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/136\">",
"       136",
"      </a>",
"      ]. The small excess risk observed was similar to what has been observed with seasonal influenza vaccines. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=see_link&amp;anchor=H10#H10\">",
"       \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Influenza vaccination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study in China that used active surveillance to identify patients with neurologic conditions in hospitals in the Beijing metropolitan area following the vaccination of 95,244 children and adults with a nonadjuvanted monovalent split-virion vaccine against pandemic H1N1 influenza A, no association was observed between vaccination and the development of Guillain-Barr&eacute; syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/123\">",
"       123",
"      </a>",
"      ]. In the postmarketing surveillance study in China discussed above, 0.1 cases of Guillain-Barr&eacute; syndrome were reported per million doses of vaccine administered, which is lower than the background rate in China [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/133\">",
"       133",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H640151200\">",
"       'Postmarketing surveillance in China'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The British Paediatric Surveillance Unit system reported only one case of Guillain-Barr&eacute; syndrome in a child younger than 17 years of age that was temporally related to administration of a whole virion nonadjuvanted pandemic H1N1 influenza vaccine; a single case within six weeks of vaccination is what would be expected by chance given the background rate of Guillain-Barr&eacute; syndrome in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a multinational case-control study in Europe that included 104 patients with Guillain-Barr&eacute; syndrome between November 1, 2009 and April 1, 2010, the adjuvanted monovalent pandemic H1N1 influenza A vaccine was not associated with an increased risk of Guillain-Barr&eacute; syndrome (adjusted odds ratio 1.0, 95% CI 0.3-2.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to the study in Europe described above, a population-based cohort study from Quebec, Canada, performed between October 2009 and March 2010 found a small but significantly increased risk of Guillain-Barr&eacute; syndrome during the eight-week postvaccination period (adjusted relative risk [aRR] 1.80, 95% CI 1.12-2.87) and during the four-week postvaccination period (aRR 2.75, 95% CI 1.63-4.62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/139\">",
"       139",
"      </a>",
"      ]. Increased risk was observed only in individuals aged 50 years or older. The number of excess cases attributable to the vaccine was approximately two per million doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H592844613\">",
"    <span class=\"h3\">",
"     Narcolepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals in several European countries have developed narcolepsy after receiving Pandemrix, an AS03 (oil-in-water emulsion)-adjuvanted 2009 H1N1 influenza vaccine. Pandemrix was used in certain countries during the 2009-2010 H1N1 influenza pandemic, but it was not used in the United States. The risk appears to be greatest in children and adolescents, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In early investigations, vaccinated children and adolescents in Finland and Sweden had a nine- and four-fold increased risk of narcolepsy, respectively, compared with unvaccinated children and adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/140\">",
"       140",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large retrospective database review that included six countries in Europe over a 10-year period, increased narcolepsy rates, primarily in children and adolescents, were observed in some (but not all) countries after the initiation of Pandemrix vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/141\">",
"       141",
"      </a>",
"      ]. The background incidence rate (IR) of narcolepsy in Europe was 0.93 per 100,000 person-years (and 0.83 per 100,000 person-years in 5 to 19 year olds). After initiation of vaccination, in the 5 to 19 year old age group, the IR of narcolepsy (per 100,000 person-years) was 7.5 (95% CI 5.2-10.7) in Sweden, 6.4 (95% CI 4.2-9.7) in Finland, and 1.9 (95% CI 1.1-3.1) in Denmark. Increases were also observed in individuals &ge;60 years of age in Finland (IR 1.9, 95% CI 1.1-3.3) and in persons between 20 and 59 years of age in Denmark (IR 1.5, 95% CI 1.2-1.9). No significant increases were observed in the Netherlands, Italy, or the United Kingdom. Sweden and Finland, the two countries with the highest incidence of narcolepsy, were the only countries that recommended vaccinating the entire population (as opposed to selected high-risk groups).",
"     </li>",
"     <li>",
"      In contrast to the database review described above, an increased risk of narcolepsy was observed in children and adolescents in a study performed in the United Kingdom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/142\">",
"       142",
"      </a>",
"      ]. Among 75 children and adolescents in the United Kingdom with narcolepsy onset after January 1, 2008, 11 had been vaccinated with Pandemrix before onset and 7 had been vaccinated within six months before onset. Among those who were diagnosed by July 2011, the odds ratio for vaccination at any time before onset was 14.4 (95% CI 4.3-48.5) and the odds ratio for vaccination within six months of narcolepsy onset was 16.2 (95% CI 3.1-84.5). The attributable risk was estimated to be between 1 in 57,500 doses and 1 in 52,000 doses.",
"     </li>",
"     <li>",
"      A case-control study in France found an association between narcolepsy and pandemic influenza vaccination (either Pandemrix or an unadjuvanted pandemic H1N1 influenza vaccine, but almost all associations were with Pandemrix) both in individuals &le;19 years (adjusted odds ratio [aOR] 5.09, 95% CI 2.10-12.26) and in adults (aOR 3.88, 95% CI 1.37-10.95) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/143\">",
"       143",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Narcolepsy is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=see_link\">",
"     \"Clinical features and diagnosis of narcolepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1047182254\">",
"    <span class=\"h3\">",
"     Other neurologic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neurologic syndromes, such as transverse myelitis and opsoclonus myoclonus syndrome, have occurred rarely following vaccination against pandemic H1N1 influenza A, although it is not clear that these adverse effects resulted from vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415333\">",
"    <span class=\"h3\">",
"     Pregnant women, fetuses, and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small trial of an inactivated pandemic H1N1 influenza vaccine in pregnant women, it was well tolerated and no safety concerns arose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/109\">",
"     109",
"    </a>",
"    ]. Furthermore, no studies have shown an increased risk of either maternal complications or adverse fetal outcomes associated with inactivated influenza vaccines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H415354\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the efficacy of vaccination against pandemic H1N1 influenza A has not been proven, a study that modeled the effectiveness and cost-effectiveness of vaccination suggested that vaccinating 40 percent of the population of a large United States city (population 8.3 million) with a vaccine that is 75 percent effective in November 2009 would avert 1468 deaths, gain 49,422 quality-adjusted life-years, and save $302 million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/145\">",
"     145",
"    </a>",
"    ]. In another analysis by the same researchers, the combination of vaccination with expanded availability of antiviral prophylaxis was also found to be effective and cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/146\">",
"     146",
"    </a>",
"    ]. Another study showed that vaccination of pregnant women against both seasonal and pandemic influenza is cost-effective when maternal and neonatal outcomes are considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624651960\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of infection control measures were recommended by public health officials during the 2009 to 2010 H1N1 influenza A pandemic. Infection control of seasonal influenza viruses in healthcare settings is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=see_link\">",
"     \"Infection control measures to prevent seasonal influenza in healthcare settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In military units in Singapore, an approach that involved enhanced surveillance, isolation of ill individuals, and segregation of units into smaller subgroups appeared to reduce transmission of 2009 H1N1 influenza A virus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/21/38234/abstract/148\">",
"     148",
"    </a>",
"    ]. A prospective observational cohort study was performed in three groups of Singapore military personnel, which included 1015 individuals in 14 units; &ldquo;normal&rdquo; units were subjected to prevailing pandemic response policies (general health eduction on respiratory and hand hygiene, instructions to seek medical attention if ill), &ldquo;essential&rdquo; units and healthcare workers had additional public health interventions (enhanced surveillance with isolation through home medical leave, segregation of units into smaller subgroups, personal protective equipment). Seroconversion among essential units (17 percent) and healthcare workers (11 percent) was significantly lower than in normal units (44 percent). Symptomatic illness attributable to influenza was also lower in essential units (5 percent) and healthcare workers (2 percent) compared with normal units (12 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In late March and early April 2009, an outbreak of H1N1 influenza A virus infection was detected in Mexico, with subsequent cases observed in many other countries, including the United States. In June 2009, the World Health Organization raised its pandemic alert level to the highest level, phase 6, indicating widespread community transmission on at least two continents. The pandemic was declared to be over in August 2010. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with confirmed or suspected influenza infection requiring treatment during the 2009 to 2010 H1N1 influenza A pandemic, a neuraminidase inhibitor (orally inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      or oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      ) was recommended. (See",
"      <a class=\"local\" href=\"#H412650\">",
"       'Oseltamivir or zanamivir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       Zanamivir",
"      </a>",
"      was the preferred agent for patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      -resistant pandemic H1N1 influenza A infection. In those who were unable to use inhaled zanamivir (eg, critically-ill patients, patients with a history of bronchospasm), the intravenous formulation was considered appropriate. (See",
"      <a class=\"local\" href=\"#H412464\">",
"       'Intravenous zanamivir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The United States Food and Drug administration issued emergency use authorization for peramivir, an investigational neuraminidase inhibitor that is administered intravenously, for the treatment of certain hospitalized and critically-ill patients with suspected or confirmed pandemic H1N1 influenza A infection. (See",
"      <a class=\"local\" href=\"#H412471\">",
"       'Peramivir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiviral therapy was recommended for individuals with suspected or confirmed pandemic H1N1 influenza A infection who were severely ill or who had risk factors for complications (eg, pregnancy, age &lt;5 or &gt;65 years, severe immunocompromise). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several observational studies of hospitalized patients with pandemic H1N1 influenza A suggested that treatment with a neuraminidase inhibitor (most commonly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      ) reduced disease severity and mortality. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of strains of pandemic H1N1 influenza A virus circulating in 2009 to 2010 were sensitive in vitro to the neuraminidase inhibitors,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/20/40263?source=see_link\">",
"       oseltamivir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/27/26038?source=see_link\">",
"       zanamivir",
"      </a>",
"      , but all strains tested were resistant to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/10/30885?source=see_link\">",
"       rimantadine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Drug resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      During the 2009 to 2010 influenza season, it was necessary for individuals to be vaccinated against pandemic H1N1 influenza A using a monovalent vaccine, since the trivalent (seasonal) influenza vaccine did not contain antigens from this strain. Starting with the 2010 influenza season in the southern hemisphere and the 2010 to 2011 season in the northern hemisphere, the trivalent influenza vaccine included antigen from the 2009 pandemic H1N1 influenza A virus. (See",
"      <a class=\"local\" href=\"#H413651\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most formulations of the 2009 pandemic H1N1 influenza vaccine were well-tolerated, individuals in several countries in Europe have developed narcolepsy after receiving Pandemrix, an AS03 (oil-in-water emulsion)-adjuvanted 2009 H1N1 influenza vaccine. The risk appears to be greatest in children and adolescents. (See",
"      <a class=\"local\" href=\"#H592844613\">",
"       'Narcolepsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:453.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Influenza-like illness in the United States and Mexico file://www.who.int/csr/don/2009_04_24/en/index.html (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. World now at the start of 2009 influenza pandemic. file://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html (Accessed on June 11, 2009).",
"    </li>",
"    <li>",
"     World Health Organization. In focus: H1N1 now in the post-pandemic period. August 10, 2010.",
" file://www.who.int/csr/disease/swineflu/en/index.html (Accessed on September 21, 2010).",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. file://www.cdc.gov/h1n1flu/recommendations.htm (Accessed on December 15, 2009).",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. Emergency use authorization (EUA) for the investigational antiviral drug peramivir. file://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187800.pdf (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/7\">",
"      Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/8\">",
"      Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/9\">",
"      H&auml;rter G, Zimmermann O, Maier L, et al. Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus. Clin Infect Dis 2010; 50:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/10\">",
"      Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/11\">",
"      Fraaij PL, van der Vries E, Beersma MF, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011; 204:777.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Antiviral treatment options, including intravenous peramivir, for treatment of influenza in hospitalized patients for the 2009-2010 season. file://www.cdc.gov/h1n1flu/EUA/peramivir_recommendations.htm (Accessed on October 26, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/13\">",
"      Yu Y, Garg S, Yu PA, et al. Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010. Clin Infect Dis 2012; 55:8.",
"     </a>",
"    </li>",
"    <li>",
"     US Centers for Disease Control and Prevention. Termination of the Emergency Use Authorization (EUA) of Medical Products and Devices, June 24, 2010. file://www.cdc.gov/h1n1flu/eua/ (Accessed on October 07, 2010).",
"    </li>",
"    <li>",
"     Ison, MG, McGeer, A, Hui, DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. XI International Symposium on Respiratory Viral Infections. 2009. Oral abstract available at file://www.themacraegroup.com/2009-symposia/xi-international-symposium-on-respiratory-viral-infections/oral-abstracts/safety-and-efficacy-of-multiple-day-treatment-with-intravenous-peramivir-or-oral-oseltamivir-in-hospitalized-adults-with-acute-influenza (Accessed October 27, 2009).",
"    </li>",
"    <li>",
"     Kohno S, et al. Single-intravenous peramivir vs. oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III randomized, double-blind trial. Abstract V-537a. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA September 12-15, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/17\">",
"      Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis 2011; 52:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/18\">",
"      Sorbello A, Jones SC, Carter W, et al. Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus. Clin Infect Dis 2012; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Updated interim recommendations for obstetric health care providers related to use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. file://www.cdc.gov/H1N1flu/pregnancy/antiviral_messages.htm (Accessed on November 03, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/20\">",
"      Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med 2009; 361:e110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/21\">",
"      Aoki FY, Hayden FG. The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic. J Infect Dis 2013; 207:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/22\">",
"      Muthuri SG, Myles PR, Venkatesan S, et al. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/23\">",
"      Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/24\">",
"      Jain S, Benoit SR, Skarbinski J, et al. Influenza-associated pneumonia among hospitalized patients with 2009 pandemic influenza A (H1N1) virus--United States, 2009. Clin Infect Dis 2012; 54:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/25\">",
"      Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341:c4779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/26\">",
"      Viasus D, Pa&ntilde;o-Pardo JR, Pach&oacute;n J, et al. Pneumonia complicating pandemic (H1N1) 2009: risk factors, clinical features, and outcomes. Medicine (Baltimore) 2011; 90:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/27\">",
"      Viasus D, Pa&ntilde;o-Pardo JR, Pach&oacute;n J, et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest 2011; 140:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/28\">",
"      Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/29\">",
"      Lee EH, Wu C, Lee EU, et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010; 50:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/30\">",
"      Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/31\">",
"      Rodr&iacute;guez A, D&iacute;az E, Mart&iacute;n-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/32\">",
"      Dom&iacute;nguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/33\">",
"      Launes C, Garc&iacute;a-Garc&iacute;a JJ, Jord&aacute;n I, et al. 2009 Influenza A H1N1 infections: delays in starting treatment with oseltamivir were associated with a more severe disease. Pediatr Infect Dis J 2011; 30:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/34\">",
"      Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/35\">",
"      Centers for Disease Control and Prevention (CDC). Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)--United States, April 2009-August 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/36\">",
"      Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/37\">",
"      Choi SM, Boudreault AA, Xie H, et al. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011; 117:5050.",
"     </a>",
"    </li>",
"    <li>",
"     Infectious Diseases Society of America. Influenza H1N1: frontline questions and expert opinion answers. file://www.idsociety.org/Content.aspx?id=15743 (Accessed on December 15, 2009).",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Interim guidance for clinicians on identifying and caring for patients with swine-origin influenza A (H1N1) virus infection file://www.cdc.gov/swineflu/identifyingpatients.htm (Accessed on May 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/40\">",
"      Wright PF, Kirkland KB, Modlin JF. When to consider the use of antibiotics in the treatment of 2009 H1N1 influenza-associated pneumonia. N Engl J Med 2009; 361:e112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/41\">",
"      Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/42\">",
"      Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators, Davies A, Jones D, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA 2009; 302:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/43\">",
"      Lai KY, Ng WY, Osburga Chan PK, et al. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 2010; 152:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/44\">",
"      Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011; 53:326.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. Recommendations for use of antiviral medications for the management of influenza in children and adolescents for the 2009-2010 season - pediatric supplement for healthcare providers file://www.cdc.gov/h1n1flu/recommendations_pediatric_supplement.htm (Accessed on December 14, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/46\">",
"      Centers for Disease Control and Prevention (CDC). Outbreaks of 2009 pandemic influenza A (H1N1) among long-term-care facility residents - three states, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/47\">",
"      Lee VJ, Yap J, Cook AR, et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N Engl J Med 2010; 362:2166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/48\">",
"      Iuliano AD, Reed C, Guh A, et al. Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis 2009; 49:1811.",
"     </a>",
"    </li>",
"    <li>",
"     United States Centers for Disease Control and Prevention. 2009-2010 influenza season week 20 ending May 22, 2010 file://www.cdc.gov/flu/weekly/ (Accessed on June 16, 2010).",
"    </li>",
"    <li>",
"     European Center for Disease Prevention and Control. Oseltamivir-resistant pandemic (H1N1) 2009 influenza virus, October 2009 file://www.ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&amp;ID=683 (Accessed on November 19, 2009).",
"    </li>",
"    <li>",
"     World Health Organization. Viruses resistant to oseltamivir (Tamiflu) identified, 8 July 2009 file://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en/ (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/52\">",
"      Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, August 30-October 31, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/53\">",
"      Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:893.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Pandemic (H1N1) 2009 - update 62 (revised 21 August 2009 file://www.who.int/csr/don/2009_08_21/en/index.html (Accessed on August 25, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/56\">",
"      Baz M, Abed Y, Papenburg J, et al. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med 2009; 361:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/57\">",
"      Le QM, Wertheim HF, Tran ND, et al. A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010; 362:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/58\">",
"      Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010; 50:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/59\">",
"      Inoue M, Barkham T, Leo YS, et al. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg Infect Dis 2010; 16:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/60\">",
"      Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011; 17:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/61\">",
"      Morlighem J&Eacute;, Aoki S, Kishima M, et al. Mutation analysis of 2009 pandemic influenza A(H1N1) viruses collected in Japan during the peak phase of the pandemic. PLoS One 2011; 6:e18956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/62\">",
"      Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/63\">",
"      Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med 2011; 365:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/64\">",
"      Hurt AC, Hardie K, Wilson NJ, et al. Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 2012; 206:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/65\">",
"      Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011; 203:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/66\">",
"      Chen LF, Dailey NJ, Rao AK, et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients--North Carolina, 2009. J Infect Dis 2011; 203:838.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Infectious Diseases Research and Policy. Clusters of resistant H1N1 cases reported in UK, US. file://www.cidrap.umn.edu/cidrap/content/influenza/swineflu/news/nov2009resistance.html (Accessed on December 08, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/68\">",
"      Calatayud L, Lackenby A, Reynolds A, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009-2010. Emerg Infect Dis 2011; 17:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/69\">",
"      Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/70\">",
"      Ghedin E, Laplante J, DePasse J, et al. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J Infect Dis 2011; 203:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/71\">",
"      Ghedin E, Holmes EC, DePasse JV, et al. Presence of oseltamivir-resistant pandemic A/H1N1 minor variants before drug therapy with subsequent selection and transmission. J Infect Dis 2012; 206:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/72\">",
"      Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011; 16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/73\">",
"      Nguyen HT, Fry AM, Loveless PA, et al. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010; 51:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/74\">",
"      van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/75\">",
"      Memoli MJ, Davis AS, Proudfoot K, et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 2011; 203:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/76\">",
"      Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009; 58:749.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Influenza-like illness in the United States and Mexico, 24 April 2009. file://www.who.int/csr/don/2009_04_24/en/index.html (Accessed on April 27, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/78\">",
"      Centers for Disease Control and Prevention (CDC). Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009; 58:433.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season file://www.who.int/csr/disease/influenza/recommendations 2010_2011north/en/index.html (Accessed on June 24, 2010).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2010 southern hemisphere influenza season file://www.who.int/csr/disease/influenza/recommendations 2010south/en/index.html (Accessed on June 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/81\">",
"      National Center for Immunization and Respiratory Diseases, CDC, Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/82\">",
"      Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009; 58:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/83\">",
"      Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/84\">",
"      Centers for Disease Control and Prevention (CDC). Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/85\">",
"      Cowling BJ, Ng S, Ma ES, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis 2010; 51:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/86\">",
"      Garcia-Garcia L, Valdespino-G&oacute;mez JL, Lazcano-Ponce E, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 2009; 339:b3928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/87\">",
"      Marcelin G, Bland HM, Negovetich NJ, et al. Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 2010; 202:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/88\">",
"      Qiu C, Huang Y, Wang Q, et al. Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin Infect Dis 2012; 54:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/89\">",
"      McCullers JA, Van De Velde LA, Allison KJ, et al. Recipients of vaccine against the 1976 \"swine flu\" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010; 50:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/90\">",
"      Xie H, Li X, Gao J, et al. Revisiting the 1976 \"swine flu\" vaccine clinical trials: cross-reactive hemagglutinin and neuraminidase antibodies and their role in protection against the 2009 H1N1 pandemic virus in mice. Clin Infect Dis 2011; 53:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/91\">",
"      Janjua NZ, Skowronski DM, Hottes TS, et al. Seasonal influenza vaccine and increased risk of pandemic A/H1N1related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis 2010; 51:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/92\">",
"      Skowronski DM, De Serres G, Crowcroft NS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med 2010; 7:e1000258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/93\">",
"      Tsuchihashi Y, Sunagawa T, Yahata Y, et al. Association between seasonal influenza vaccination in 2008-2009 and pandemic influenza A (H1N1) 2009 infection among school students from Kobe, Japan, April-June 2009. Clin Infect Dis 2012; 54:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/94\">",
"      Echevarr&iacute;a-Zuno S, Mej&iacute;a-Arangur&eacute; JM, Mar-Obeso AJ, et al. Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/95\">",
"      Glezen WP. How did the 2008-2009 seasonal influenza vaccine affect the pandemic? Clin Infect Dis 2010; 51:1380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/96\">",
"      Neuzil KM. Pandemic influenza vaccine policy--considering the early evidence. N Engl J Med 2009; 361:e59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/97\">",
"      Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/98\">",
"      Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/99\">",
"      Talaat KR, Greenberg ME, Lai MH, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 2010; 202:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/100\">",
"      Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/101\">",
"      Khurana S, Verma N, Talaat KR, et al. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J Infect Dis 2012; 205:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/102\">",
"      Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/103\">",
"      Wu J, Li W, Wang HQ, et al. A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis 2010; 202:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/104\">",
"      Nicholson KG, Abrams KR, Batham S, et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 2011; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/105\">",
"      Jackson LA, Chen WH, Stapleton JT, et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 2012; 206:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/106\">",
"      Roman F, Vaman T, Kafeja F, et al. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/107\">",
"      Ferguson M, Risi G, Davis M, et al. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis 2012; 205:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/108\">",
"      Jackson LA, Patel SM, Swamy GK, et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 2011; 204:854.",
"     </a>",
"    </li>",
"    <li>",
"     NIH News. Initial results show pregnant women mount strong immune response to one dose of 2009 H1N1 flu vaccine file://www.hhs.gov/news/press/2009pres/11/20091102a.html (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/110\">",
"      Ohfuji S, Fukushima W, Deguchi M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 2011; 203:1301.",
"     </a>",
"    </li>",
"    <li>",
"     NIH News. Early results: In children, 2009 H1N1 influenza vaccine works like seasonal flu vaccine. September 21, 2009 file://www.nih.gov/news/health/sep2009/niaid-21.htm (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     NIH News. Updated Results: in youngest children, a second dose of 2009 H1N1 influenza vaccine elicits robust immune response file://www.niaid.nih.gov/news/newsreleases/2009/pages/interimpedsdata.aspx (Accessed on October 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/113\">",
"      Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/114\">",
"      Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/115\">",
"      Hadler JL, Baker TN, Papadouka V, et al. Effectiveness of 1 dose of 2009 influenza A (H1N1) vaccine at preventing hospitalization with pandemic H1N1 influenza in children aged 7 months-9 years. J Infect Dis 2012; 206:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/116\">",
"      Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010; 362:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/117\">",
"      Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010; 340:c2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/118\">",
"      Walker WT, de Whalley P, Andrews N, et al. H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clin Infect Dis 2012; 54:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/119\">",
"      Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/120\">",
"      Monkman K, Mahony J, Lazo-Langner A, et al. The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies. Leuk Lymphoma 2011; 52:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/121\">",
"      Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/122\">",
"      Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011; 118:6769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/123\">",
"      Wu J, Xu F, Lu L, et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010; 363:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/124\">",
"      Andrews N, Waight P, Yung CF, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 2011; 203:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/125\">",
"      Ortqvist A, Berggren I, Insulander M, et al. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 2011; 52:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/126\">",
"      Uzicanin A, Thompson M, Smith P, et al. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine. J Infect Dis 2012; 206:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/127\">",
"      Vajo Z, Tamas F, Sinka L, Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010; 375:49.",
"     </a>",
"    </li>",
"    <li>",
"     Pandemic 2009 influenza update: Pandemrix data on co-administration with annual seasonal influenza vaccine (Fluarix) file://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10127.htm (Accessed on November 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/129\">",
"      Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/130\">",
"      Destefano F, Tokars J. H1N1 vaccine safety monitoring: beyond background rates. Lancet 2010; 375:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/131\">",
"      Centers for Disease Control and Prevention (CDC). Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/132\">",
"      Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010; 28:7248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/133\">",
"      Liang XF, Li L, Liu DW, et al. Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. N Engl J Med 2011; 364:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/134\">",
"      Evans D, Cauchemez S, Hayden FG. \"Prepandemic\" immunization for novel influenza viruses, \"swine flu\" vaccine, Guillain-Barr&eacute; syndrome, and the detection of rare severe adverse events. J Infect Dis 2009; 200:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/135\">",
"      Landaverde JM, Danovaro-Holliday MC, Trumbo SP, et al. Guillain-Barr&eacute; syndrome in children aged &lt;15 years in Latin America and the Caribbean: baseline rates in the context of the influenza A (H1N1) pandemic. J Infect Dis 2010; 201:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/136\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary results: surveillance for Guillain-Barr&eacute; syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. MMWR Morb Mortal Wkly Rep 2010; 59:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/137\">",
"      Verity C, Stellitano L, Winstone AM, et al. Guillain-Barr&eacute; syndrome and H1N1 influenza vaccine in UK children. Lancet 2011; 378:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/138\">",
"      Dieleman J, Romio S, Johansen K, et al. Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe. BMJ 2011; 343:d3908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/139\">",
"      De Wals P, Deceuninck G, Toth E, et al. Risk of Guillain-Barr&eacute; syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012; 308:175.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Global Advisory Committee on Vaccine Safety. Statement on narcolepsy and vaccination, 21 April 2011. file://www.who.int/vaccine_safety/topics/influenza/pandemic/h1n1_safety_assessing/narcolepsy_statement/en/index.html (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/141\">",
"      Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013; 31:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/142\">",
"      Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794.",
"     </a>",
"    </li>",
"    <li>",
"     European Centre for Disease Prevention and Control. Narcolepsy and Pandemrix vaccine &ndash; an association in adults as well as children. file://ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f%2D77d4%2D4ad8%2Db6d6%2Dbf0f23083f30&amp;ID=1289&amp;RootFolder=%2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20Reviews (Accessed on February 28, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/144\">",
"      Denholm JT, Neal A, Yan B, et al. Acute encephalomyelitis syndromes associated with H1N1 09 influenza vaccination. Neurology 2010; 75:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/145\">",
"      Khazeni N, Hutton DW, Garber AM, et al. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med 2009; 151:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/146\">",
"      Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Ann Intern Med 2009; 151:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/147\">",
"      Beigi RH, Wiringa AE, Bailey RR, et al. Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis 2009; 49:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/21/38234/abstract/148\">",
"      Lee V, Yap J, Cook AR, et al. Effectiveness of public health measures in mitigating pandemic influenza spread: a prospective sero-epidemiological cohort study. J Infect Dis 2010; 202:1319.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7011 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-CBD0E914AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38234=[""].join("\n");
var outline_f37_21_38234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H412091\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414876\">",
"      Antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H412650\">",
"      - Oseltamivir or zanamivir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H412464\">",
"      - Intravenous zanamivir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H412471\">",
"      - Peramivir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532740\">",
"      Antibacterial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H532747\">",
"      Other treatment modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2914387\">",
"      - Extracorporeal membrane oxygenation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2914394\">",
"      - N-acetyl cysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H533005\">",
"      - Effect of glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H412957\">",
"      ANTIVIRAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5183765\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H413372\">",
"      Prophylaxis in closed settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      DRUG RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neuraminidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12594437\">",
"      - H274Y mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12594466\">",
"      - S247N mutation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12594473\">",
"      - Multidrug resistance mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Adamantanes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H413651\">",
"      VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414235\">",
"      Cross-protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414242\">",
"      Possible increased risk following seasonal influenza vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414256\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414264\">",
"      - Laboratory assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414271\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414278\">",
"      - Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414285\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414769\">",
"      - HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H624651914\">",
"      - Solid organ transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H74638892\">",
"      - Patients with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11840296\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H414292\">",
"      Coadministration of pandemic H1N1 and seasonal influenza vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415304\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415319\">",
"      - Vaccine Adverse Event Report System (VAERS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H640151200\">",
"      - Postmarketing surveillance in China",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415326\">",
"      - Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H592844613\">",
"      - Narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1047182254\">",
"      - Other neurologic syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H415333\">",
"      - Pregnant women, fetuses, and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H415354\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H624651960\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/60/39880?source=related_link\">",
"      Antiviral drug resistance among seasonal influenza viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37305?source=related_link\">",
"      Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/2/31786?source=related_link\">",
"      Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37863?source=related_link\">",
"      Extracorporeal membrane oxygenation (ECMO) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/34/2599?source=related_link\">",
"      Infection control measures to prevent seasonal influenza in healthcare settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/48/25354?source=related_link\">",
"      Inpatient treatment of pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=related_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=related_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/7/39032?source=related_link\">",
"      Treatment and prevention of avian influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=related_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_21_38235="Noninfectious pneumonia";
var content_f37_21_38235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63652&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Noninfectious etiologies of nonresolving pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplastic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchogenic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchoalveolar cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunologic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vasculitis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diffuse alveolar hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiolitis obliterans-organizing pneumonia (BOOP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Eosinophilic pneumonia syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute interstitial pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary alveolar proteinosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary vascular abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38235=[""].join("\n");
var outline_f37_21_38235=null;
var title_f37_21_38236="ACC AHA ESC doses conversion AF";
var content_f37_21_38236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Recommended doses of drugs (listed alphabetically) proven effective for pharmacological cardioversion of atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route of administration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosage&Delta;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Potential adverse effects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Amiodarone",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       <p>",
"        Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total, then 200 to 400 mg per day as single dose",
"       </p>",
"       <p>",
"        Outpatient 600 to 800 mg/day divided dose until 10 g total, then 200 to 400 mg per day maintenance",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypotension, bradycardia, QT prolongation, torsade de pointes (rare), GI upset, constipation, phlebitis (IV use)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous (IV)/oral",
"      </td>",
"      <td>",
"       5 to 7 mg/kg over 30 to 60 min, then 1.2 to 1.8 g per day continuous IV or in divided oral doses until 10 g total, then 200 to 400 mg per day maintenance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dofetilide",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Creatinine clearance (mL/min):",
"        </strong>",
"       </p>",
"       <p>",
"        Greater than 60: 500 mcg BID",
"       </p>",
"       <p>",
"        40 to 60: 250 mcg BID",
"       </p>",
"       <p>",
"        20 to 40: 125 mcg BID",
"       </p>",
"       <p>",
"        Less than 20: Contraindicated",
"       </p>",
"      </td>",
"      <td>",
"       QT prolongation, torsade de pointes; adjust dose for renal function, body size, and age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Flecainide",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       200 to 300 mg&bull;",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypotension, rapidly conducting atrial flutter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       1.5 to 3.0 m per kg over 10 to 20 min&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ibutilide",
"      </td>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       1 mg over 10 min; repeat 1 mg when necessary",
"      </td>",
"      <td>",
"       QT prolongation, torsade de pointes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Propafenone",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       450 to 600 mg",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypotension, rapidly conducting atrial flutter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       1.5 to 2.0 mg per kg over 10 to 20 min&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quinidine&loz;",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       0.75 to 1.5 g in divided doses over 6 to 12 h, usually with a rate-slowing drug",
"      </td>",
"      <td>",
"       QT prolongation, torsade de pointes, gastrointestinal upset, hypotension",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &Delta; Dosages given in the table may differ from those recommended by the manufacturers.",
"     <br>",
"      &bull; Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease or impaired left ventricular function, and these drugs should be used cautiously or not at all in such patients.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38236=[""].join("\n");
var outline_f37_21_38236=null;
var title_f37_21_38237="ACG Rx IBS 2009";
var content_f37_21_38237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2009 American College of Gastroenterology (ACG) recommendations for the treatment of irritable bowel syndrome (IBS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diet and irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patients often believe that certain foods exacerbate their IBS symptoms. There is, however, insufficient evidence that food allergy testing or exclusion diets are efficacious in IBS and their routine use outside of a clinical trial is not recommended.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of dietary fiber, bulking agents, and laxatives in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psyllium hydrophilic mucilloid (ispaghula husk) is moderately effective and can be given a conditional recommendation. A single study reported improvement with calcium polycarbophil. Wheat bran or corn bran is no more effective than placebo in the relief of global symptoms of IBS and cannot be recommended for routine use. Polyethylene glycol (PEG) laxative was shown to improve stool frequency - but not abdominal pain - in one small sequential study in adolescents with IBS-C.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of antispasmodic agents, including peppermint oil, in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Certain antispasmodics (hyoscine, cimetropium, pinaverium, and peppermint oil) may provide short-term relief of abdominal pain / discomfort in IBS. Evidence for long-term efficacy is not available. Evidence for safety and tolerability is limited.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of antidiarrheals in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The antidiarrheal agent loperamide is not more effective than placebo at reducing pain, bloating, or global symptoms of IBS, but it is an effective agent for the treatment of diarrhea, reducing stool frequency, and improving stool consistency. Randomized controlled trials comparing loperamide with other antidiarrheal agents have not been performed. Safety and tolerability data on loperamide are lacking.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of antibiotics in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A short-term course of a nonabsorbable antibiotic is more effective than placebo for global improvement of IBS and for bloating. There are no data available to support the long-term safety and effectiveness of nonabsorbable antibiotics for the management of IBS symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of probiotics in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In single organism studies, lactobacilli do not appear effective for patients with IBS; bifidobacteria and certain combinations of probiotics demonstrate some efficacy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of the 5-HT",
"       <sub>",
"        3",
"       </sub>",
"       receptor antagonists in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The 5-HT",
"       <sub>",
"        3",
"       </sub>",
"       receptor antagonist alosetron is more effective than placebo at relieving global IBS symptoms in male and female IBS patients with diarrhea. Potentially serious side effects including constipation and colon ischemia occur more commonly in patients treated with alosetron compared with placebo. The benefits and harms balance for alosetron is most favorable in women with severe IBS and diarrhea who have not responded to conventional therapies. The quality of evidence for efficacy of 5-HT",
"       <sub>",
"        3",
"       </sub>",
"       antagonists in IBS is high.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of 5-HT",
"       <sub>",
"        4",
"       </sub>",
"       (serotonin) receptor agonists in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The 5-HT",
"       <sub>",
"        4",
"       </sub>",
"       receptor agonist tegaserod is more effective than placebo at relieving global IBS symptoms in female IBS-C patients and IBS-M patients. The most common side effect of tegaserod is diarrhea. A small number (0.11 percent) of cardiovascular events (myocardial infarction, unstable angina, or stroke) were reported among patients who had received tegaserod in clinical trials.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of the selective C-2 chloride channel activators in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lubiprostone in a dose of 8 micrograms twice daily is more effective than placebo in relieving global IBS symptoms in women with IBS-C.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of antidepressant agents in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) are more effective than placebo at relieving global IBS symptoms, and appear to reduce abdominal pain. There are limited data on the safety and tolerability of these agents in patients with IBS.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of psychological therapies in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psychological therapies, including cognitive therapy, dynamic psychotherapy, and hypnotherapy, but not relaxation therapy, are more effective than usual care in relieving global symptoms of IBS.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Effectiveness of herbal therapies and acupuncture in the management of irritable bowel syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Available randomized controlled trials mostly tested unique Chinese herbal mixtures, and appeared to show a benefit. It is not possible to combine these studies into a meaningful meta-analysis, however, and overall, any benefit of Chinese herbal therapy in IBS continues to potentially be confounded by the variable components used and their purity. Also, there are significant concerns about toxicity, especially liver failure, with use of any Chinese herbal mixture. A systematic review of trials of acupuncture was inconclusive because of heterogeneous outcomes. Further work is needed before any recommendations on acupuncture or herbal therapy can be made.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IBS: irritable bowel syndrome; IBS-C: constipation-predominant irritable bowel syndrome; IBS-M: mixed irritable bowel syndrome; 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     : 5-hydroxytryptamine (serotonin) 3 receptor agonists; 5-HT",
"     <sub>",
"      4",
"     </sub>",
"     : 5-hydroxytryptamine (serotonin) 4 receptor agonists.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: American College of Gastroenterology IBS Task Force. An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome. Am J Gastroenterol 2009; 104:S1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38237=[""].join("\n");
var outline_f37_21_38237=null;
var title_f37_21_38238="Bedbug bites 2";
var content_f37_21_38238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bedbug bites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A bedbug bite most often appears as a wheal with a central hemorrhagic punctum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nigel Hill, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38238=[""].join("\n");
var outline_f37_21_38238=null;
var title_f37_21_38239="Three piece penile prosthesis";
var content_f37_21_38239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Three piece penile prosthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of American Medical Systems, Minnetonka, Minnesota. www.AmericanMedicalSystems.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_21_38239=[""].join("\n");
var outline_f37_21_38239=null;
